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Abstract
Postoperative wound site infections remain a major source of illness with approximately
500,000 infections per year, among an estimated 27 million surgical procedures. Such infections
account for approximately one quarter of the estimated 2 million nosocomial infections in the United
States which causes about 90,000 deaths each year. More than 70% of the bacteria that causes
such infections are resistant to at least one of the antibiotics and result in longer hospitalization;
besides requiring second option treatments that may be less effective, more toxic and expensive.
Hence, there is a frenetic search for alternatives and in this regard, antimicrobial peptides and
metallic nanoparticle like silver and copper, which possess broad spectrum antimicrobial activity
and evince low rates of resistance, are touted to play major roles. This study looks to achieve two
major objectives-1) to tackle surgical site infections specifically due to hernia meshes, using a novel
antimicrobial peptide as a coating and 2) to explore the possibility of using copper nanoparticles
as a viable alternative to nanocrystalline silver in topical wound dressings, wherein it performs the
dual role of preventing infections and promoting wound healing. With regards to the first objective,
the study demonstrated that both synthetic and biological meshes coated with the enzyme were
active against S.aureus, the pathogenic species of interest. The bactericidal effect could largely
be attributed to leached enzyme in the case of synthetics but to a lesser extent in the case of
biologics. The long term viability of this coating was proven by performing accelerated one year
equivalent shelf life studies; with no apparent loss in enzyme activity. Also, the protective effects
of the biologic mesh against denaturation of the enzyme during sterilization and lyophilization
were noted. All these results indicate that such a peptide based coating could act as a viable
alternative to currently available antibiotic therapy in treating mesh related infections. The progress
made on the second objective is basically restricted to analyzing the infection control aspect and
host cell cytotoxicity of these copper nanoparticles. 2 nm copper nanoparticles stabilized with
ii

polyacrylic acid were synthesized and antibody attachment was carried out by physical adsorption.
An optimum antibody: nanoparticle ratio of 1:1 showed a six times and ten times lower minimum
inhibitory concentration (MIC) than the bare nanoparticles, for two different strains of P.aeruginosa.
However, this effect was not significant for gram positive S.aureus and varying the antibody ratio
did not affect the MICs. The antibody effect was only seen at a low nanoparticle concentration
and this could be a possible reason why its effect was relatively less pronounced in S.aureus, as its
possesses a significantly higher MIC than P.aeruginosa; proving that its less susceptible to these
copper nanoparticles. Also, the mechanism of antibody related targeting needs to be investigated
as non-specific antibody produced the same effect as that of the specific antibody. This is probably
due to the fact that the antibodies, which can theoretically bind a few nanoparticles per molecule,
lead to a local increase in nanoparticle concentration when they encounter bacteria and this effect
is prominent only at low nanoparticle concentrations. The host cytotoxicity issues associated with
the usage of such metallic nanoparticles was studied using MTT assay and it showed that the
nanoparticles were more toxic towards the fibroblasts than bacteria even at sub MIC concentrations
thereby practically ruling out its applicability as a topical wound healing agent. Hence, work needs
to be done to possibly encapsulate these particles into a biocompatible matrix thereby preventing
host cytotoxicity while selectively attracting bacteria into it by providing directional cues. The
approaches developed here are universal and can potentially be used for treatment of other surgical
device-associated infections.
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Chapter 1

Introduction
Postoperative wound site infections remain a major source of illness with approximately
500,000 infections per year, among an estimated 27 million surgical procedures. Such infections account for approximately one quarter of the estimated 2 million nosocomial infections in the United
States each year which causes about 90,000 deaths each year. More than 70% of the bacteria that
cause hospital-acquired infections are resistant to at least one of the antibiotics most commonly used
to treat them. People infected with antibiotic-resistant organisms are more likely to have longer hospital stays and require treatment with second- or third-choice medicines that may be less effective,
more toxic, and more expensive. In this thesis, Chapter 2 begins by providing an overview of the
wound healing process, and the therapeutic role of copper in wound healing. This is followed by
studying of wound microbiology, colonization and approaches in controlling wound microbial populations. Thereafter, the differences in gram positive and gram negative cell wall and rise of antibiotic
resistant strains, which has led to the search for alternatives to antibiotics, is discussed. In this context, antimicrobial peptides and copper nanoparticles as alternatives are examined. The final topic
deals with development of hernia, non-infectious and infectious complications associated with mesh
usage; and current approaches to deal with such infectious complications. In chapter 3, we propose
to specifically tackle surgical site infections due to hernia meshes, using a novel antimicrobial peptide
coating. Bacterial infections by S. aureus, the most common pathogen found in approximately 90%
of mesh infections with more than 60% being antibiotic-resistant; are among the most common postoperative complications in surgical hernia repair with infection rates varying from 1 to 18% according
to different studies. Lysostaphin, an antimicrobial enzyme developed by a competing S. staphylolyti1

cus strain specifically targets and cleaves S. aureus cell walls, thus effectively killing the bacteria.
The feasibility of utilizing this enzyme as an antimicrobial coating for meshes requires in vitro and
in vivo demonstration of its antimicrobial activity. In this regard, Lysostaphin-impregnated meshes
have recently been found to be highly efficient in preventing staphylococcal infections in animal experiments by Heniford et al. This work basically looks at the in vitro validation of such an enzyme
coating. For this purpose, adsorption isotherms were acquired by fluorescently labeling lysostaphin
and this was used to achieve identical lysostaphin coatings for different meshes. Next, the leaching
profiles of the various meshes were evaluated and fractional analysis was performed on select meshes
to determine if the activity was due to bound or leached enzyme. Approval of such meshes for
clinical use requires demonstration of sufficient long-term storage stability; and so the final goal of
this study was to investigate effect of accelerated aging and sterilization on antimicrobial activity of
such lysostaphin coated biological and synthetic meshes. To this end, select enzyme-coated meshes
were subjected to accelerated aging studies for upto 3 weeks at 60C or 10 weeks at 50C. Accelerated
aging periods at these temperatures correspond to one year shelf life if stored at room temperature.
The freeze dried enzyme coated meshes were also exposed to two e-beam dosages of 10, 25 KGy for
sterilization purposes and its effect on the enzyme antimicrobial activity was evaluated. In Chapter
4, the possibility of using copper nanoparticles as an alternative to nanocrystalline silver; in topical
wound dressings is studied. The work basically restricts itself to analyzing the infection control
aspect and host cell cytotoxicity of these copper nanoparticles. Antibody directed targeting and the
optimum antibody: nanoparticle ratio that would maximize this effect was explored, with the aim
of reducing the working concentration of such nanoparticles, thereby alleviating the possible toxicity
issues associated with the usage of such metallic nanoparticles. Chapter 5 summarizes the research
findings and derives conclusions from the above two studies. Finally, recommendations and possible
future studies are discussed.

2

Chapter 2

Literature Review
2.1

Wound healing- An Overview
Wound healing is an extremely organized and intricate process that can be summed up

by four distinct phases: Hemostasis, Inflammation, Proliferation and Remodeling [51], [154]. The
four phases though sequential, often co-occur. The moment the tissue is injured, a set of complex
biochemical events takes place in a closely orchestrated manner. The blood components spill into
the site of injury causing the platelets, also known as thrombocytes, to come into contact with the
other elements of the extracellular matrix. Within minutes the platelets aggregate to form a fibrin
clot, which acts to control active bleeding [154].
Once the bleeding is controlled, the next task is the removal of foreign materials damaged
tissues and bacteria. This is done by the neutrophils that enter the wound site and attach themselves
to the endothelial cells.
As the process continues, the fixed tissue macrophages move into the area of injury and
transform into highly functional active wound macrophages. These highly phagocytic macrophages
are involved in eliminating the foreign debris, damages matrix, the neutrophils engorged with bacteria and other non-functional host cells [22]. Once the wound site is cleaned, factors are released that
cause the migration and cells involved in the proliferative phase to divide. This phase is characterized by TGF-β released by the platelets, and regulates a host of fibroblast functions. The master
control signal, TGF-β has a three-branched effect [33]: I.First, it increases the overall production
of matrix proteins by the transcription of the genes for collagen, proteoglycans and fibronectin.
3

Figure 2.1: The neutrophils (Margination) migrating to the wound site by chemotaxis-by the signals
from the bacteria (Diapedesis) and ingest them through phagocytosis. (Image courtousy: Gadi
Borkow, 2004. Coppers Role in Wound Healing. Cupron Inc).
II.Second, TGF-β also decreases the secretion of proteases,which cause a breakdown of the matrix
and III.Finally, stimulates the protease inhibitor and tissue inhibitor of metallo-protease (TIMP).
The last process in wound healing is development of new skin in place of the dead tissues.
The process of epithelization is accentuated by EGF (epidermal growth factor) and TGFα that are
produced by activated wound macrophages, platelets and keratinocytes [161].
The low oxygen and nutrient content of the surroundings induced by the rapid metabolic
activity demand a new blood supply and speed angiogenesis. Angiogenesis or neovascularization is
stimulated by vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (bFGF)
and TGF β. The fibroblast is the predominant cell of the proliferative phase and this cell is in charge
of restoring the structure and function to the injured tissue by producing the new collagen matrix.
Finally this collagen becomes highly cross-linked by the action the enzyme lysyl oxidase and forms a
stable structure [33]. The inflammation step is very critical during wound healing. Healing proceeds
only after the inflammation is controlled. During fibrosis, there is excessive matrix deposition and
reduced remodeling which are characterized my lesions which are linked with high mast cell densities.
All chronic wounds have bacterial colonization. Most of these bacteria do not contribute positively
to the wound healing process. Large number of factors like bacterial count, the species the host
immune response, the virulence of the microbes and mutually beneficial interactions between the
different species decide if the colonies can cause infection [51]. There is increasing proof that the
infectious microbes within chronic wounds reside in biofilm communities, thereby not only protecting
4

themselves from host defenses but ultimately proving to be resistant to antibiotics as well [56].

2.2
2.2.1

Role of Copper in wound healing
Angiogenesis and copper
Vascular endothelial growth factor (VEGF) is the most significant signal that stimulates

angiogenesis, which plays an important role in wound healing. Although it is known that copper is
involved in the facilitation of this process [125], [12], [13], its specific targets remained unclear, until
a recent study identified the cytokines involved in the angiogenic effects of copper [79]. In in vivo and
in vitro models, it was found that CuSO4promotes both angiogenesis and VEGF expression [155].
The effect of Cu2+ on inducible VEGF was however not influenced by H202; it depended on the
thiol-redox state of the cells. Topical application of CuSO4 not only promoted closure of excisional
murine dermal wounds but also positively affected the quality of the regenerating tissue. The density
of cells in granulation layer and VEGF expression were also found to be clearly higher. Moreover,
chelation of copper reduced the vascular response to injury [141], [99]. Thus, this angiogenic potential
of copper can be used to promote dermal wound contraction and closure and hence copper based
therapeutics promise a feasible approach to wound healing.

2.2.2

Fibronectin and copper
Fibronectin is a large extracellular matrix cell adhesion protein and functions in wound

repair by promoting angiogenesis and organizing matrix deposition. Purified plasma fibronectin can
be developed into 3dimensional mats (fn-mats) [10], which are of great value in tissue engineering.
The stability of these mats can be increased by treatment with cu ions. This increase in stability
is however dose dependent. Dissolution of proteins from fn-mat with 1µM copper (lowest concentration) increased the stability 3- to 4-folds at room temperature and 2-folds at 37C. Similarly, the
orientation of fn fibers within the mat was retained when treated with 1 µM Cu, but was distorted
at higher concentrations. Schwanncontinue cells grew, without reduction in cell number, in cultures
with fn-mats stabilized by 1 µM cu but growth was inhibited at 10-200 µM concentrations. Thus,
fn-mats can be stabilized and cell ingrowth can be increased by low concentrations of copper (1 µM)
and this stabilization technique produces longer survival in vitro [9].

5

2.2.3

Integrins and copper
ntegrins that are expressed by basal layer kerationocytes, such as alpha2beta1, alpha3beta1,

alpha6beta4 and alphaVbeta5, are involved in wound healing. Their expression and distribution in
the epidermis are modified during re-epithelialization. Their expression in specific is induced in
vitro by trace elements such as Zn, Cu and Mn. Zn induces integrins affecting cellular mobility
in proliferation phase (alpha3, alpha6, alphaV) and Cu induces those expressed by suprabasally
differentiated keratinocytes during the final phase of wound healing (alpha2, beta1, alpha6). Mn on
the other hand has mixed effects [147].

2.2.4

Copper dependent enzymes involved in wound healing
Cu2+ dependent formation of multi-protein complexes containing s100a13 protein releases

fgf1, a pro-angiogenic polypeptide, in response to stress [122], and Cu2+ chelation represses this
release. Thus, Cu2+chelators act as anti-cancer agents; given their capability of restricting the export of these pro-inflammatory and angiogenic signal peptide-less polypeptides into the extracellular
compartment [100]. Cu-dependent enzymes such as amine oxidases which are involved in remodeling
and healing are found to increase during wound healing [162], [98], [126], [89], [86]. Lysyl oxidase
catalyzes the formation of aldehyde cross links and acts on collagen and elastin during wound healing
[33]. Topical application of Zn and Cu allows the up regulation of metallothionein gene in skin and
in wound margins of high mitotic activity. Metallothioneins are low molecular weight proteins containing 30% cysteine. This induction in wound margin reflects its role in promoting cell proliferation
and re-epithelialization [91].

2.3

Wound Microbiology and colonization
The most common infective species in wound healing are facultative aerobic bacterial species

like S.aureus, coagulase negative Staphylococci, Enterococcus species, Escherichiacontinue Coli and
Enterobacter species which account for 60-80% of the total flora [35]. However, a lot of experts
suggest that anaerobic bacteria (includes Peptostreptococcus, Clostridium and Bacteriodes species)
which account for 20-40% are the invisible villains who are not given enough attention but are
highly virulent [34]. The reasons for this failure are attributed to the fact that anaerobes are not
regarded as detrimental to wound healing ,identification is time consuming, labor intensive and fi6

nally they are perceived to die quickly upon air exposure and therefore method of sample collection
and transportation becomes very important [55]. Wounds are generally susceptible to microbial
colonization due to: Low partial pressure of oxygen (< 20mmHg for wounds and < 30mm Hg for
tissues) due to oxygen consumption by aerobic bacteria and disrupted blood supply, which lead to
reduced redox potential and pH of the tissue which greatly helps anaerobic microbial growth resulting in a polymicrobial flora. Now nutrients produced by them help growth of virulent co-inhabiting
aerobic species. Anaerobic bacteria concentrate succinate, which compromises immune response
and prevents phagocytosis of aerobic species like S.aureus and E.coli, thus producing a favorable
microenvironment [103]. Purulent discharge and cellulitis are typical infection symptoms and the
infected state depends on a range of microbial and host factors besides site, size, depth and type of
wound. Dirty surgical procedures are susceptible to 27% risk of infection due to endogenous contamination, while acute soft tissue infections pose a risk due to 50% of them possessing a polymicrobial
symbiotic aerobic-anaerobic microflora [106]. Bite wound infections range from 10-50% while 75%
of burn wound deaths are because of infections [34]. Diabetics are five times more susceptible to
infections because elevated glucose levels result in greater succinate production and its more active
at this low pH, hypoxic and necrotic region [2].

2.4

Control of Microbial population in wounds
Treating wounds has been well documented through the earliest known civilizations and has

remained until today. The various methods and classes of treatments used shall be summarized in
the Table 2.1 [111] below. Despite the existence of various treatment options, usage of antibiotics
continues to be the most prominent and widely utilized method of treating bacterial infections

2.5

Bacterial cell wall
Bacterial cells walls have been important clinical targets for antibiotics and these are com-

prised of polysaccharide chains cross-linked through peptides containing D-amino acids [152]. The
primary function of the bacterial cell wall is to provide a rigid structure to protect it against both
osmotic and mechanical lysis [135]. It also serves as an attachment site to the proteins that interact
with the bacteria [87].
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General
Group
Antiseptic

Purpose
Kill or inhibit growth
of
various
organisms on
the external
surfaces of
the body.

Antimicrobial Inhibition of
bacterial repopulation

Debridement

Removal of
non-viable
tissue

Pressured mechanism
of action
Cell Destruction

Creation of an acidic environment.
Exact mechanism unknown
Acidic environment
Alkaline environment
Osmolytic effect
Inhibition of bacterial synthesis or disruption of the
cell membrane
Drainage of exudate, bacteria or toxins
Stimulation of the immune response
Creation of hypoxic environment
Creation of hyperoxic environment
Digestion and ingestion
Mechanical

Chemical
Enzymatic
Autolytic
Wound
sure

clo-

Facilitate
wound closure

Creation of a moist environment increases angiogenesis, stimulates fibroblasts and induces reepithelization

Products
Hydrogen peroxide, alcohol, iodine, mercury, silver, chlorhexidine, sodium
hypochloride.

Slow release antiseptics.
Iodine compounds, silver
compounds, silver sulphadiazine.
Wine, vinegar, acetic acid,
carboxy acid.
Myrrh and frankincense,
vegatbles, plants
Sugar, honey
Maggots
Sugar, honey
Topical antibiotics

Vacuum therapy
Honey
Semi/ Occlusive dressings,
Vacuum therapy
Hyperbaric therapy
Maggots
Wet to dry gauze, ultrasound assisted wound debridement, whirlpool, irrigation or pulsed lavage
Sodium hypochlorite, Hydrogen peroxide
Honey, papain, maggots,
collagenase
Hydrogels, hydrocolloids,
honey
Semi-occlusive dressings,
alginates, collagen, honey,
silver releasing compunds,
vacuum assisted wound
closure, hyperbaric oxide

Table 2.1: Different types of Wound treatment methods (31). (Image courtesy: Moues et al Five
Millennia of Wound Care Products - what is new? A Literature Review, Ostomy Wound management
2009; 55(3):1632).
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Figure 2.2: Differences between Gram positive and Gram negative cell walls [1]. Image courtesy of
http://filebox.vt.edu/users/chagedor/biol 4684/Methods/cellwalls.html
Bacteria are generally classified based on their cell wall structure in Figure 2.2 namely as
a) Gram-positive and b) Gram-negative bacteria. Gram-positive bacteria have a cell wall that is
comprised of peptidoglycan and are thick mesh-like that stain purple; while Gram-negative bacteria
have a relatively thinner layer, which stain pink on the gram stain test results. Although majority
of the bacteria stick to the color differentiation of the Gram stain, some bacteria do not; these
are called Gram-variable bacteria [28]. Gram-positive bacteria have a peptidoglycan macromolecule
cell wall attached to accessory molecules such as polyphosphates, carbhohydrates, teichoic acids and
teichuronic acids [135],[72]. In comparison to gram negative bacteria, they have a much thicker peptidoglycan layer and no external cell membrane. Unlike gram negative bacteria, they also dont possess
periplasmic space-i.e. the zone between the cytoplasmic and outer membrane. The glycan strands
of the cell wall comprise-repeating disaccharide N-acetylmuramic acid-(b1-4)-N-acetylglucosamine
(MurNAc-GlcNAc) [66], [67]. Glycan strands contain 5 to 30 subunits, varying based on the type
of the bacterial species [144], [75]. Wall peptides generate a three-dimensional structure owing to
the cross-linking of the different peptides that attach themselves to the neighboring glycan strand.
Muramic acid is associated with bacterial cell walls and these chains are cross-linked by chanins
consisting of L and D amino acids [148], [149].
For antibiotics that inhibit bacterial cell wall synthesis the peptidoglycan is a well-known
target [3]. The peptidoglycan is unique cell wall component with respect to all the bacteria and not
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Species

%
of
isolates
from
nosocomial
infections

E. Faecium
S.aureus
K.Pneumoniae
A.Baumanni
P.Aeruginosa
Enterobacter
spp
Total %

5.6%
14.5%
5.8%
2.7%
7.9%
4.8%

% drug resistant

Amp
90%

Meth
80%
63%

N.A

N.A

Vanc

3GCs

Cbpms

24%
33%
25%
N.A

8.7%

56%

11%
N.A

N.A

41.3%

Table 2.2: ESKAPE Pathogens and their rates of antibiotic resistance (Table recreated from Hidron
AI, et al. 2008; Infection control and Hospital Epidemiology; 29:996-1011)

the eukaryotic cells. Hence it is an excellent target that the immune system of the host recognises
[137], [29]. The gram-positive envelope is constituted by the plasma membrane and the cell wall
[27], [124]. Gram-negative bacteria have cell walls that are composed of three layers, an inner bilayer
phospholipid membrane, a thin peptidoglycan layer and the outer bi-layer membrane, composed of
lipopolysaccharides [29], [27]. E.coli and other Gram-negative bacteria contain two distinct lipid
by-layers; and in between lies the peptidoglycan containing periplasmic space that represent the
inner membrane and the outer membrane [124], [54]. The inner membrane of e-coli is composed of
phospholipids along with peripheral membrane proteins. The inner membrane carries out functions
like ATP synthesis, electron transport, biosynthesis and cell signaling [52].
The Outer membrane is an asymmetric lipid bilayer that is unique and consists of phospholipids and lipopolysaccharide (LPS), which are present in the inner face and outer face respectively.
The outer membrane does the nutrient uptake and it provides the organism with functionalities like
permeability barrier, conferring resistance to a variety of agents including antibiotics [116].

2.6

Antibiotic resistant Pathogens
The most common and widespread drug resistant microbes are the ESKAPE Pathogens [77]

shown in Table 2.2:
The two predominant antibiotic resistant species responsible for nosocomial infections are
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discussed in the next section.

2.6.1

Staphylococcus aureus
Staphylococcus aureus is a facultative anaerobic which is Gram-positive. Coccus refers to

being single and in pairs and in irregular clusters. Staphylococcus aureus is not motile, does not
form spores, catalase and coagulase positive bacterium. Staphyle is greek term which means a bunch
of grapes. It can form colonies and infect both categories-healthy people and hospitalized patients
with reduced host defense mechanisms [64]. Its virulence factors are deadly. Both structural and
secreted products play a role in pathogenesis of infection. Increased regulation of the production
of the virulent factors enables it to persist in the blood stream, adhere and colonize the skin and
mucosa, evade the host immune response, form protective biofilms through quorum sensing and also
develop resistance against a wide range of antibiotics.
S. aureus have a unique and inherent ability to produce biofilms on damaged tissue, prosthetic materials such as medical devices and heart valves. This makes it difficult to treat than
planktonic bacteria. Biopolymers such as proteins and polysaccharides and lipids compose the
biofilm, this makes it difficult for antimicrobial agents penetration [70]. The cells that live in biofilms
display a complex arrangement of various extracellular components and form some secondary structures, which demonstrate complete resistance against conventional antibiotics, likes microcolonies
and small-colony variants (SCVs) [68].
The S. aureus biofilm formations involve two stages 1.) Adhesion of cells initially to a
surface mediated by surface proteins, these serve as an anchor 2.) This is followed by production of
extracellular factors that enable cell multiplication and maturation into a structured community.
Quorum-sensing system increases the expression of secreted virulence factors based on bacterial density and decreases the expression of cell surface proteins [164]. The infection rate is dependent on both community and hospital-acquired strains; and the treatment of these infections is also
becoming more difficult because of the increasing prevalence of multidrug-resistant strains [165].

2.6.2

Pseudomonas Aeruginosa
It is a Gram-negative, aerobic, rod-shaped bacterium with unipolar motility. [133] An

opportunistic human pathogen, P. aeruginosa is the type species of the genus Pseudomonas (Migula)
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[15]. The reason why P.aeruginosa is extremely resistant to antibiotics is due to the combination
of multiple factors such as low cell wall permeability, resistance mechanisms that are regulated by
chromosomal mutation; and an ability to acquire additional resistance genes from other organisms
via plasmids, transposons and bacteriophages [90]. Also in the lungs, where they cause cystic fibrosis
they are generally covered by an alginate polysaccharides which makes them resistant to drugs [115].
P. aeruginosa biofilms are encased in a protective alginate polysaccharide and this makes
them extremely drug resistant. Also, other reasons for this resistance include high bacterial cell
density and physical exclusion of the antibiotic. To combat a challenge, metabolic processes are also
shut down and protective mechanisms are induced. It is clear that cells in the biofilm can sense
the presence of other cells (quorum sensing) and alter their properties accordingly. Finally, there is
tremendous heterogeneity in the population within a biofilm- containing fast- and slow-growing cells,
some resistant through expression of inactivating enzymes and efflux pumps, others conspicuously
not expressing such systems [90].

2.6.3

Alternatives to antibiotics
With the growth of drug resistant microbes, there is a frenetic search for alternatives in the

fight against multidrug resistant pathogens. In this regard, this review shall look into the prospect of
using antimicrobial metallic nanoparticles, specifically copper nanoparticles, and peptides/enzymes
as able substitutes in this fight against these pathogens.

2.6.4

Antimicrobial proteins (AMPs) and peptides
Proteins and peptides have attracted attention due to their antimicrobial property and

its approach is devoid of antibiotics [109], [101], [4]. Peptides and enzymes that occur naturally
have been identified to have higher broad antimicrobial spectrum, and the low rate of resistance to
these agents by bacteria [73]. Defensins, cathelicidins, and histatins are three different groups of
antimicrobial peptides that are part of the immune system, and in mammals they are generally found
in phagocytic cells and in mucosal epithelial cells. Antibacterial enzymes have been classified based
on their functionality as hydrolases or oxidoreductases [43]. Hydrolasess functionality is defined
by its ability to breakdown the structural cell wall components of bacteria. The osmotic balance
of the cell is ruptured leading to degradation. The enzymes are then further grouped into N-
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acetylhexosaminidases that catalyze the cleavage of the β (l-4)-glucosidic linkages in the carbohydrate
backbone of the peptidoglycan, and N-acetylmuramyl-L-alanine amidases that catalyze the cleavage
of the carbohydrate and peptide moiety of the peptidoglycan. The final class called endopeptidases
hydrolyzes the peptide crosslinks of the peptidoglycan [156]. In our work, we use lysostaphin,
a murein hydrolase that cleaves the cross-linked pentaglycine bridges in the peptidoglycan of S.
aureus resulting in the rupture of the cell walls due to hydrolysis.

2.6.5

Challenges associated with application of antibacterial proteins and
peptides
Antimicrobial proteins and peptides have found great prospects and enthusiasm with re-

gards to its development. The major drawbacks of using enzymes and peptides in a clinical setting
are high manufacturing cost, especially of peptides, short half-life in vivo, loss of activity in physiological conditions (especially at high ionic strength, which may interfere with their charge-directed
targeting and mechanism of action), unwanted systemic reactions (aggregation, immunoreactivity),
interference with normal bacterial flora and even site-specific delivery that may arise when attempts
are made to use them for targeted delivery as antibacterial agents.
It is well known that small molecules that are lesser than 70kDa have a comparatively
shorter half-life in blood after intravenous administration, for example enzymes and peptides. Rapid
clearance from circulation could potentially reduce its efficacy as an antimicrobial. Enzymes such as
lysostaphin are basically derived from bacteria and they are concerns regarding immunogenicity in
humans, thereby leading to its clearance from the blood stream. This is due to the specific humoral
response [47], [20]. Antibodies released from the host could also neutralize the enzymes and hence
lead to lower efficacy of the drug. This is the reason why the half-life cannot be effectively taken care
from increasing the dosage. Synthesis of recombinant protein, which is a more expensive approach,
has also been tried out. The recombinant protein is resistant to proteolytic degradation [105].

2.6.6

Metallic Nanoparticle as Bactericidal agents
Scientists over the last decade have reverted to using heavy metals as possible bactericides.

In this regard, both silver and copper, which have been used since ancient times, have received
the most attention. Also, the development of nanoscience and nanotechnology in the last decade
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presented opportunities for researching the antibacterial properties of metal nanoparticles; whose
small size and high surface to volume ratio, allows it to interact closely with microbial membranes
as against a mere release of metal ions in solution [131].Application of metal nanoparticles has
immense potential with respect to medical instruments and devices, given that it can be either
coated or immobilized on surfaces to exhibit its bactericidal activity. However their in-vivo toxicity
remains a concern and needs careful evaluation. This review focusses on copper and its various
antimicrobial mechanisms, given that it proposes to study copper nanoparticle as a topical wound
healing agent.

2.6.7

Mechanism of Copper’s Antimicrobial Action
Copper binds to thiol groups and Oxygen sites better than essential metals, hence disrupt-

ing structure and function. Vitamin E, an antioxidant, turns into a DNA damaging agent and
epinephrine, dopamine kill growing E.coli cells in the presence of Cu2+(work by nanohorizons and
Cupron Inc.). Cuprous ions mimic effects of microwave induced damage to DNA helix by inducing
crosslinks within and between strands [134].Copper also causes cellular leakage and lipid peroxidative
damage to the bacterial cell wall [40], [118]. Some complexes like DDCs (Diethyldithiocarbamic acid)
antimicrobial activity greatly increases due to amphipathic complexes with Cu, which concentrate
in the lipid bilayer disrupting membrane integrity [8].

2.6.8

Mechanisms of Resistance to copper
The various mechanisms utilized by bacteria for resisting heavy metal toxicity include:
1) Metal Exclusion by the permeability barrier-usually due to altered membrane channel

porins in E.coli [130] and periplasmic proteins in Pseudomonas aeruginosa [78]. 2) Active Transport away from the microorganism by an ATPase efflux mechanism in some gram positive bacteria
[145]. 3) Intracellular-seen in Pseudomonas putida [142] and Extracellular Sequestration -observed
in pseudomonas biofilms [146]. 4) Enzymatic Detoxification due to transplasma membrane redox
systems and metal ion reductases [158]. 5) Decrease in metal sensitivity of cellular targets (seems
to be more effective in gram negative bacteria as against gram positive ones) [108].
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2.7

Anatomical classification of Hernias and Statistics
A hernia is the protuberance of an organ or its fascia through the wall of the cavity that

normally contains it. Hernias are caused by two major factors- muscle weakness and strain. In this
regard, surgical hernia intervention is the most common elective procedure in general surgery with
1.1 million hernia operations performed annually in the US [16]. The two major techniques used in
such hernia repair include Tension free and Laparoscopic repairs. The weak points in the abdominal
wall are the inguinal, umbilical and femoral canal regions which account for approximately 73%,
9.5% and 2.7% of the total cases respectively. Incisional hernia accounts for nearly 11% of the
remaining 15% of the cases and the rest are due to relatively rare epigastric, hiatal and spigelian
hernias [119]. However, unfavorablerecurrencerates for hernia repairs are as follows: Inguinal hernia15 to 30% [140] and Ventral hernia-50% [74]. This has led to the usage of meshes during surgical
management to reduce such recurrences.

2.8

Advent of Meshes and its associated noninfectious complications
In recent times, mesh usage has become a standard solution for hernia repair surgery all

around the globe and has shown to reduce hernia recurrence rates. For example, the uses of a
mesh for the repair of incisional hernias have been found to decrease its recurrence in many studies
by an average of 30% [76], [97], [139]. According to Vrijland et al. a randomized clinical trial
involving 289 patients were conducted and a comparison between non-mesh and mesh repair for
primary inguinal hernia were studied. The recurrence rate was 7% for the non-mesh technique and
1% for the mesh technique [157]. The complications with mesh usage include seromas, adhesions,
chronic severe pain, migration, rejection of the mesh and infections related to the mesh. Relatively
biocompatible and inert surgical meshes have been the focus in recent years, since it has been noted
that surgical meshes could trigger various responses when implanted in the human body. These
were commonly observed to be inflammation, thrombosis, fibrosis, calcification and infection. Some
proteins such as albumin and fibrinogen have been found to initially be absorbed by the surface of
the polymer; this is termed as foreign body reactions. Consecutively the physiochemical properties
of the polymers lead to the degradation of the proteins that were absorbed. This results in the
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simulation of macrophages that respond by releasing growth factors and inflammatory substances.
Then there are other inflammatory cells like T-lymphocytes, polymorphouclear cells, eosinophils,
plasma cells and fibroblasts are attracted to the polymer surface. This leads to granulomas which
are characterized by increased cell turnover locally that could extend to a several years after mesh
implantation in the human body. The foreign bodies reaction also depends on mesh surface area
that is in the contact with the body of the host [127].
Meshes are generally made of a non-absorbable polymer that has been used extensively in
clinical practice. Some of them are polyester, polypropylene and expanded polytetrafluroethylene.
Newer meshes are made of a combination of a non-absorbable and absorbable polymer [82], [36].
The properties (mechanical and biological) of the meshes depend on the type of tissue structure and
fiber used [48]. Also, the pore size plays a major role in the safety and tolerance of these surgical
meshed [84].

2.9

Infectious complications associated with Mesh usage
Infections related to mesh implantation occur less frequently when compared to other device

related infections. However, they are of high clinical importance to both patients and surgeons. A
current study, done involving 200 patients on the implications of umbilical hernia repair with or
without meshes, indicated that the rate of post-operative complications (including infections) were
similar using both the procedures [17]. It was the same when 20 trials of 5016 participants where done
for groin repairs [71]. On the other hand, in 160 patients with simple or complex hernia underwent
suture, skin graft or mesh repair the rate of infections were lower in suture repair than skin graft or
mesh repair. Mesh implantation also led to an increase in the rate of infections on repairing both
simple and complex hernias [88]. There is a great interest as to whether the type of material or
the technique for hernia repair used has an influence on the incidence of mesh infections. However,
most of these studies were not focused precisely on mesh related infection rates. Leber et al. [94]
conducted an analysis of 200 patients who underwent an open repair of abdominal incisional hernias
with prosthetic material. They determined if the surgical technique was influenced by the long-term
complications. It was determined that the exact surgical technique did not have any major influence
on the long-term complications. Many authors have suggested that the laparoscopic approach to
repair hernia have very few post-operative complications when compared to the open repair, but there
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are no clear indications or data related to mesh infection rates [104], [37], [41]. Recently published
papaers have suggested that the incidence of mesh-related infections have comparable results with
respect to clean surgical procedures and especially in cases; where a possibly contaminated surgical
procedure was carried out at the same time as the incisional hernia repair. [65], [31].

2.10

Microbiology of related Mesh infections
The main organisms that are involved with mess-related infections are Staphylococcus

species, especially that of Staphylococcus aureus. Mesh-related infections were studied and majority or about 63% of the microorganisms present were methicillin-resistant S.aureus also known
as MRSA [44]. In very rare scenarios mesh infections are also caused by Candida species or Mycobacterium species [117], [102]. Mesh infections can spread with chronic, persistent or recurring
symptoms. The infecting agents in most of the reported cases were small colonies of S. aureus.
These infections respond very poorly to antimicrobial treatments [69].

2.11

Current strategies in Preventing mesh related Infections
Surgeons work at trying to minimize the surface area of the mesh, introduced during the

hernia operation, because the inserted foreign body is an ideal growth medium for bacteria [50].
Four main approaches for the prevention of mesh-related infections have been used. First, the
wound should be rinsed with an antibiotic solution immediately after the the hernia sac dissection,
and then repeated at frequent intervals until the skin is sutured. When tried on animals, this
method has been shown to inhibit the adhesion of bacteria to the surface [150]. In a randomized
trial of 162 patients underwent inguinal hernia repair, there were no evidence of any kind of wound
infections after a single dose of cefamadole on the wound [92]. Antibiotics require a defined duration
of contact with pathogens. Hence lavage effectiveness with antimicrobial agents is controversial as
they are usually a more rapid process.
In the second method a material is placed in front of the mesh in order to deliver an antimicrobial agent locally. This method resulted in very few post-operative infections when compared
to patients undergoing surgical repair for the hernia without the use of this method [113]. Thirdly
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a mesh containing the embedded antimicrobial agents can be used. Finally a traditional intravenous perioperative administration of antimicrobial agents can be used [166], [38]. Although all of
these above techniques were effective with respect to mesh-related infections, none of these can be
a definitive recommendation in the absence of comparative outcome data. Currently perioperative
administration of intravenous antibiotics is still being used until new strategies become available.
The use of gentamicin-laced collagen tampons with a mesh is best reserved for patients with a high
risk of infections, such as those that are diabetic and obese.
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Chapter 3

Comparitive in Vitro Performance
and Long-term Storage Stability of
Lysostaphin-coated Synthetic and
biological Hernia meshes
3.1

Introduction
Prosthetic mesh usage for closure of defects during ventral and incisional herniorrhaphy

has exhibited significantly reduced cumulative recurrence rates by around 30% after short- and
long-term follow-up[160], [153], [95]. However, mesh repair, continues to be plagued by several postimplantation complications of which infection, remains a severe and ubiquitous complication, with
an incidence rate of around 3-18% [83]. In this regard, S.aureus is the most common pathogen found
in approximately 90% of mesh infections with more than 60% of those bacteria being antibioticresistant [58] and this is further complicated by the growing prevalence of obesity, diabetes and
usage of immunosuppressive drugs in patient population [62], thus rendering them more susceptible
to possible implant related infections.
In this regard, it is important to note that mesh type, surgical technique employed and the
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strategy used to prevent infections are all significant factors that need to be evaluated while combating mesh related infections [62]. With regard to synthetic meshes, effect of actual mesh material
and type of yarn-monofilament/multifilament has received a lot of scrutiny in relation to associated
infections. It has been noted that usage of synthetic multifilament polyester mesh as against other
types of synthetic meshes (knitted/woven monofilament polypropylene, PTFE) resulted in a higher
rate of infection and fistula fomation [49]. Another important factor that has been relatively less
studied with respect to mesh infection has been the pore size; wherein microporous multifilament
meshes (≤10µm meshes) are generally associated with higher infection, possibly due to the inability
of macrophages and neutrophils(10-15 microns) to penetrate the mesh pores, while macroporous
monofilament meshes exhibit greater erosion and adhesion related complications [85]. However,
besides pore size, hydrophobicity, intrinsic ability to generate electro-static attractive forces and
surface roughness all need to be accounted while judging a meshs inherent susceptibility to bacterial
infections [143]. The subsequent advent of absorbable and bioprosthetic meshes; with the aim of
reducing foreign material in abdominal wall repair, show improved viability in contaminated surgical
fields, and increased resistance to infection [6]. However, the biological counterparts are only able to
eliminate bacterial loads upto 104 CFU/ml and fail in the case of moderate infection challenges (106
CFU/ml)[24].Hence, despite making advances in mesh design and composition, infections remained
a constant threat and different preventive and infection management strategies have been developed
to try combating this menace.
In this regard, treatment strategies basically comprise of four options which include intravenous administration of antimicrobial agents [93]; use of a material in front which slowly delivers an
antimicrobial agent e.g. gentamicin laced tampons [114]; use of a mesh embedded with antimicrobial agents [45] and finally rinsing of the wound with antibiotic solution, after hernia sac dissection
[39]. The issues surrounding the usage of antibiotics encompass various issues like risk of new drug
resistant species, loss of useful microflora and relative ineffectiveness against bacteria residing in
biofilms [151]. Also, recent clinical trials have proven the inhibitive side effect profiles attributed
to usage of antibacterial silver/chlorohexidine impregnated meshes despite their ability to combat
infections. Hence, the inability to tackle biofilms and implant associated infections result in mesh
excision, thereby increasing the possibility of recurrence of an even larger hernia than earlier [45].
In recent times, peptide based antimicrobials have received a lot of attention due to their ability
to target the species of interest by penetrating biofilms [53]. In this regard, bacteriocins, a class of
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ribosomally synthesized bacteriolytic peptides, have been studied extensively, with lysostaphin, a
class III bacteriocin, receiving a lot of attention [23]. Lysostaphin a zinc metalloenzyme, produced
by S. simulans biovar staphylolyticus, exhibits glycine-glycine endopeptidase activity and hence is
capable of lysing the cell walls of S.aureus, which is quite unique and different from other staphylococci species as it possesses pentaglycine cross bridges and higher glycine content as against greater
serine content seen in other resistant staphylococci species [23]. Previous work done in our lab by
Satishkumar et al([136], has looked at utilizing this biofilm penetrating enzyme [98], as coatings for
hernia meshes, thus highlighting its potential in treating possible hernia mesh related infections.
This paper shall look at expanding upon the previous study by comparing the adsorption and leaching profiles of lysostaphin on different biological and synthetic mesh types, while also evaluating the
enzymes long term stability and activity. Finally, work shall also been done on studying the impact
of post processing procedures like sterilization on such peptide coated antibacterial meshes, thereby
throwing some light on its practical applicability as an antibacterial coating for hernia meshes.

3.2

Materials and Methods
Preceptrol cultures of S.aureus (ATCC#27660) were obtained from American Type Culture

Collection (Manassas, VA). AMBICIN LT M (recombinant lysostaphin expressed in E.coli) was obtained from AMBI Products LLC (Lawerence, NY). Bovine Serum Albumin (BSA) was acquired from
Sigma Aldrich (St. Louis, MO). StratticeT M , AlloDerm (Life Cell, Branchburg, NJ), PermacolT M ,
PariatexT M composite (Covidien, Mansfield, MA), BardT M ( Davol, Warwick, RI),HydrocoatT M and
STS PolyproT M (Promethean Surgical Devices, LLC, East Hartford, CT) were donated by Carolinas
Medical Center (Charlotte, NC). Alexa Fluor 594 Carboxylic acid, Succinimidyl ester dyes used for
fluorescent labeling were purchased from Invitrogen, Molecular Probes (Carlsbad, CA). Microsep
Centrifugal Devices with a modified Polyethersulfone membrane (low protein binding; MWCO- 3K)
used for enzyme purification were purchased from Pall Life Sciences (Ann Arbor, MI). All other
reagents were purchased from Fisher Scientific (Pittsburgh, PA), and used without further purification unless otherwise specified. Type 1 Clear Borosilicate glass vial (25 mL) was with attached
screw caps was bought from VWR (West Chester, PA).
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3.2.1

Fluorescent labeling of lysostaphin
Fluorescent labeling of lysostaphin was done using Alexa Fluor 594 dye due to its improved

resistance to photo bleaching [25]. Approximately 5µg of Alexa Fluor 594 ( 73,000) was dissolved in
500 µL of dimethylformamide and 100 µL of this solution was added to 2 mL of a 1 mg/mL solution
of lysostaphin in 150mM PBS buffer. The enzyme was incubated for two hours with the dye at 37◦ C,
and centrifuged 25 mins at 3,500 g using a membrane centrifugal device called MicroSep (MWCO
3K) to remove any unbound dye followed by resuspension of the labeled enzyme in PBS buffer.

3.2.2

Adsorption isotherm of lysostaphin-impregnated meshes
3x3 mesh pieces cut under sterile conditions and depending on the mesh type-i.e. if biological

or composite in nature, the meshes were soaked in a 150mM PBS solution for 5 mins before carrying
out the adsorption study. Lysostaphin was weighed out under sterile conditions in an eppendorf
in order to prepare an Alexa Fluor 594 - labeled 1mg/ml stock solution. Using this stock solution,
solutions containing varying lysostaphin concentrations of 0.025, 0.05, 0.1, 0.3, and 0.5 mg/ml were
made upto the required volume using 150mM PBS solution. The initial fluorescence intensities of
these solutions (200 ul) were measured in a 96 well plate (costar) using a microplate reader (Ex
594 nm; Em 625 nm). The meshes were then placed flat in a wide mouthed flat bottom amber jar
and incubated in 3 ml lysostaphin solution for an hour on the mesh at 37◦ C under mild shaking
(100rpm). After incubation the supernatant was removed and collected for determining binding
yield. An additional 3 ml of fresh 150mM PBS was added and. this was followed by vigorous
shaking (250rpm) for 10 mins for each of these meshes. The wash fluid was collected to remove
the loosely bound enzyme. The washing step was once again repeated and the concentration of the
bound enzyme was calculated by subtracting the flourescence of the supernatant from the initial
concentrations corresponding flourescence. The flourescence of the wash fluid was not taken into
account while determining the amount of bound enzyme. The adsorption study was repeated twice
for the various candidate meshes.

3.2.3

Equivalent loading of lysostaphin onto different meshes
In order to determine the best candidate mesh based on in vivo performance, equivalent

enzyme loading onto different meshes was carried out. The amount of lysostaphin bound (as ex-
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plained in the earlier section) when incubated with an initial lysostaphin concentration of 100 and
50 ug/ml (L-100 and L-50 resp) onto Alloderm TM was determined in order to extrapolate the
initial lysostaphin loading concentration that would result in the same amount of enzyme being adsorbed onto these different meshes. The loading concentrations were determined from the obtained
adsorption isotherms of these various meshes. Once the initial concentration was determined, the
experimental verification of whether this initial loading actually produced equivalent enzyme loading
was verified using the same procedure as detailed in the earlier section. The equivalent concentrations that produced equal amount of enzyme binding among all the tested meshes were used for
subsequent turbidimetric, leaching, fractional analysis and shelf life testing studies.

3.2.4

Leaching Study
Leaching of bound lysostaphin is an important parameter to be examined while determining

the effectiveness of such antibacterial meshes. In this regard, we tried to monitor in vitro leaching
over 72 hrs since nosocomial infections occur within this time frame given that the average hospital
stay for laparoscopic and open repair groups is

4 and 6 days respectively [128]. To mimic in vivo

conditions, leaching was done in the presence of 2% (20mg/ml) BSA-150mM PBS solution. In vivo
experiments done by Satishkumar et.al. [136] have shown the effectiveness of L-100 lysostaphin
concentration. For this purpose, meshes, placed in 25 ml amber jars, were incubated in fluorescently
labeled lysostaphin solution, with equivalent Alloderm L-100 initial concentrations for 1 hour and
washed according to the earlier mentioned adsorption protocol. 200 ul of initial lysostaphin solution
utilized for these various meshes was retained so as to obtain a standard curve, to determine the
leached fraction. Also, a control mesh, without lysostaphin, was incubated in 150mM PBS solution
under the same conditions as mentioned in the adsorption protocol. The jars were then wrapped in
aluminum foils, after adsorption, to prevent photo bleaching of fluorescently labeled enzyme. This
was followed by incubation of the meshes, under mild shaking, in 3 ml of 2% BSA at 37◦ C for
72 hrs. 200 ul aliquots, containing the leached enzyme, were collected at specified time points.
Simultaneously, the same volume of 2% BSA-150mM PBS was added to the meshes at each of
these time points so as to maintain the existing 3ml volume present before withdrawal. 100 ul
from these aliquots were used for flourescence measurements. A standard curve was obtained for
100 ul of labeled enzyme; after performing a two-fold serial dilution of 1mg/ml labeled lysostaphin
using a microplate reader. (Ex 594nm and Ex 625 nm resp). The amount of leached enzyme was
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obtained from the standard curve after subtracting the fluorescence value of control from that of the
sample fluorescence value at each time point and all flourescence measurements of the standards and
unknown were done simultaneously. The fraction of leached enzyme was calculated using the known
amount of enzyme adsorbed onto the mesh after adsorption and plotted as a function of time.

3.2.5

Turbidimetric activity assay
As per the instructions of the vendor, ATCC, the S. aureus cell suspension was grown by

inoculating 15 ml of 3% (w/v) tryptic soy with 100 L of S. aureus culture. Mid-log phase growth
was achieved by incubating the cells at 37◦ C for 18 - 24 h. The cells were then pelleted at 8,000 g for
10 min and resuspended in 150mM PBS to obtain a final optical density of ∼0.6 at 600 nm. 1 mL of
cells containing ∼108 CFU (colony forming units) was added to vials containing 1X1 mesh samples.
The samples(StratticeTM, AllodermTM, PermacolTM, BardTM, HydrocoatTM, STS PolyproTM,
PariatexTM) were incubated with the cell suspension at 37◦ C under continuous shaking, and the
rate of bacterial lysis was monitored for 24 hrs by taking 0.2 mL aliquots from the reaction mixture
and measuring the optical density at 600 nm in a 96 well plate at different time intervals.

3.2.6

Fractional analysis of enzyme activity
Fractional analysis was done to ascertain if enzyme activity came predominantly from immo-

bilized or leached enzyme. Samples (StratticeT M , STS PolyproT M , HydrocoatT M and PariatexT M )
with L-100 Alloderm equivalent coating concentrations were prepared in duplicates using the previously described procedure. Incubation of these meshes in 25 ml amber glass jars containing 3 mL of
2% (w / v) BSA-150mM PBS solution was carried out for 24 h at 37◦ C. Meshes were removed from
one set of samples at varying time intervals (1, 4, 12, 24, hrs) while the other set of samples containing the meshes with the same amount of bound enzyme were left untouched. At respective time
points 1.5 ml of leached enzyme solution is removed from both the set of samples for all meshes. A
S. aureus suspension was incubated at 37◦ C for 18-25 hrs to obtain a mid-log phase and centrifuged
at 8000 g for 10 min, and resuspended in 150mM PBS to achieve a final optical density of ∼0.95 at
600 nm. 1.5 ml of this cell suspension was added to the 25 ml amber glass jars containing both the
set of samples and the resultant optical density of this mixture was 0.54 at 600 nm. The samples
were incubated with the cell suspension at 37◦ C under continuous shaking, and the rate of bacterial

24

lysis was monitored for 30 mins by taking 0.2 mL aliquots from the reaction mixture and measuring
the optical density at 600 nm in a 96 well plate along with the standards of varying lysostaphin at
different time intervals. This process was done for both sets of samples at the respective time points
to compare the leached versus total enzyme activity of the different mesh types.

3.2.7

Accelerated Shelf life testing of lysostaphin impregnated hernia
meshes
The shelf life study was carried out to determine the long term retention of enzyme activity

a crucial parameter for obtaining regulatory approval for such enzyme coatings. For this purpose,
1X1 cm StratticeT M , HydrocoatT M , PolyproT M and BardT M meshes with equivalent lysostaphin
coatings were used for shelf life testing. This was done to determine the best candidate mesh
for possible commercialization. The mesh pieces, placed in clear glass vials, were coated with L100 Alloderm equivalent coating concentration and washed according to the adsorption protocol.
Subsequently, different freezing and freezing drying protocols were carried out to optimize and
retain enzyme activity at the end of lyophilization. For this purpose, vials containing the meshes
were covered with parafilm and placed at -80◦ C freezer for different time intervals of 1,2, 4 and
12 hours so as to optimize the freezing time and subsequently freeze dried for another 12 hours.
The meshes were removed and placed into Dispos-a-vent, medical grade pouches provided by Oliver
Tolas Healthcare Packaging (Hamilton, Ohio). Prior to placing these meshes, the pouches were
purged with 99% pure compressed nitrogen gas for 5 mins and then the meshes were placed within
the pouches using forceps, which were cleansed with ethanol, and heat sealed. We then performed
shelf life experiments by placing all the candidate meshes at 60◦ C for 3 weeks. For those meshes
that showed loss of activity during this regimen, new samples were prepared as explained in this
section and placed at 50◦ C for 10 weeks. The accelerated shelf life period at both these temperatures
correspond to one year shelf life if stored at room temperature [28]. Lysostaphin activity testing
of these enzyme coated meshes was carried out every week to ensure that the enzymes activity
remained intact.
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3.2.8

Retention of enzyme activity after E-beam sterilization
The samples (1x1 StratticeT M and BardT M for the study were prepared in the same way as

mentioned in the previous section and sent to E-beam services Inc (Lebanon, Ohio) for sterilization.
Two dosages of 10KGy and 25 KGy were applied for sterilization purposes. The pouches were
returned to us by fedex the next day and used for further testing. The turbidimetric assay, as
previously described, was carried out immediately to determine if the activity of the immobilized
enzyme had been affected the sterilization process.

3.3
3.3.1

Results
Comparative Analysis of Lysostaphin binding onto Biological and
synthetic meshes
The binding yield of lysostaphin onto the various 3x3 mesh pieces was determined by floures-

cence measurements as described above. Figure 3.1, which shows the binding yield of lysostaphin/mg
of mesh for various initial loading concentrations of 25, 50, 100, 300 and 500 ug/ml. Controls, included plain meshes without lysostaphin. It is quite clear that the synthetic meshes bind greater
amounts of enzyme per milligram of mesh compared to their biological counterparts. In the case of
synthetic meshes like BardT M and HydrocoatT M , it is quite obvious that at lower concentrations
the enzyme adsorption/mg of mesh increases proportionally to the loading concentration before
seemingly hitting a plateau at the higher concentrations of 300 and 500 ug/ml. However, loading concentrations beyond 500ug/ml (data not shown),did result in increased binding in the case
of Bard TM mesh, leading to the possibility of multilayered adsorption, as described previously
by Satishkumar et. al [136] for UltraproT M mesh. It is interesting to note that the microporous
monofilament knitted polypropylene mesh-STS PolyproT M is able to bind increasing amounts of
enzyme compared to a large pore sized monofilament knitted polypropylene counterpart-BardT M at
the same loading concentrations, suggesting that smaller pore sizes helps in improved immobilization of the enzyme [107] compared to larger ones, which could possibly result in dislodgement of
enzyme molecules, during the adsorption process. Also, HydrocoatT M , a microporous polypropylene mesh coated with polyurethane, and PariatexT M composite, a hydrophilic polyester mesh,
seem to adsorb lesser amounts of lysostaphin compared to their microporous but more hydropho-
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Figure 3.1: Adsorption Isotherm of Alexa Fluor-594 labeled Lyostaphin onto 3x3 cm Biological and
Synthetic meshes (n=2).
bic polypropylene counterpart- STS PolyproT M at the respective loading concentrations, suggesting
that the hydrophilic surfaces could play a role in reducing the extent of enzyme interaction with
the mesh surface [96]. Thus the mesh material seems to play a significant role in amount of enzyme adsorbed. PariatexT M composite, a polyester mesh containing a hydrophilic coating based
on porcine collagen, PEG and glycerol, has an adsorption isotherm similar to synthetic meshes but
at higher loading concentrations greater than 500ug/ml(data not shown), it showed linear adsorption characteristics similar to its biological counterparts-i.e. Alloderm

TM

, an acellular cadaveric

dermal implant, PermacolT M , acellular crosslinked porcine dermal collagen, and StratticeT M , non
crosslinked porcine dermal matrix, all of which showed very similar and linearly increasing adsorption isotherms in response to initial loading concentrations. The enzyme adsorption was done on the
dermal side of AllodermT M and onto the polyester side of PariatexT M Composite. It is important
to note this as performing the study on the basement portion of AllodermT M or the hydrophilic film
of PariatexT M composite may result in very different adsorption isotherms.
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Figure 3.2: Experimental verification of the amount of lysostaphin adsorbed by various 3x3 cm
meshes using Alloderm equivalent L-50 and L-100 loading concentrations.

3.3.2

Equivalent loading of Lysostaphin onto different meshes
The initial loading concentration that produced equivalent enzyme loadings onto the various

meshes was done by normalizing it with respect to amount of enzyme bound for an initial loading
concentration of 50(L-50) and 100 (L-100) ug/ml of lysostaphin on AllodermT M . This was chosen
so that the in vivo performance of the various meshes could be compared. This was decided after
previous in vivo experiments carried out by Satishkumar et al. [136] showed that initial loading
concentrations of 50ug/ml onto PariatexT M and UltraproT M was insufficient in clearing an inoculum
of 5X105 CFU but subsequent experiments (data not shown) showed that the amount of enzyme
adsorbed for an initial concentration of 50ug/ml of lysostaphin onto AllodermT M did prove to be
sufficient in preventing bacterial colony formation. It can be inferred from Figure 3.2, that the
synthetics require a higher initial loading concentration to produce an equivalent L-50 and L-100
coating compared to their biological counterparts. This may appear to be in contradiction to the
previous section but it should be understood that the total amount of enzyme adsorbed at each
loading concentration was greater for the biological meshes when compared to the composite and
synthetic meshes. Experimental verification of equivalent initial concentrations produced enzyme
loading values that were ∼10-15% off the corresponding L-50 and L-100 values for AllodermT M .
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Figure 3.3: Standard Curve-Flourescence vs. different known lysostaphin concentrations (ug/ml).
However, these were considered acceptable and within the error range inherent to the flourescence
detection in the microplate reader.
Note: The value above each of the bars indicates initial loading concentration (ug/ml) and
not total amount of adsorbed enzyme.

3.3.3

Leaching Study
In a multi component protein system, competitive adsorption onto synthetic and biological

matrices may result in enzyme desorption [14] and this reality needs to be accounted when determining the viability of such a device coating. The study intended at monitoring the leaching of
the peptide coating over 72 hrs [128]. This timeframe was chosen, as the major aim of the peptide
coating was to prevent nosocomial infections that most likely occur within this period (21). 2%
BSA-150mM PBS solution was used to mimic the physiological conditions to hopefully ascertain
the in vivo leaching pattern. The amount of enzyme leached was determined from the standard
curve as shown in Figure 3.3 Flex HDT M an acellular allograft similar to AllodermT M was used as
a substitute to study leaching from allografts.
The study only used L-100 equivalent loading concentrations for the various meshes, as
previous in vivo studies by Satishkumar et al. [136] showed that an initial loading concentration
of 100ug/ml produced viable coatings that were of clinical significance. From Fig.4, it can be
determined that the enzyme leaching at the end of 72 hrs varied from 6% to 32% for the various
meshes. An interesting pattern that could be observed was the fact that the enzyme leaching at 3
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Figure 3.4: Leached fraction of adsorbed lysostaphin as a function of time for various 3x3 cm mesh
samples treated by L-100 equivalent initial loading concentrations in 2% BSA.(n=2)
hrs was close to or greater than the final amount of enzyme leached at the end of 72 hrs. Prime facie,
this suggests that there is an initial burst release followed by minimal leaching for the subsequent
time points. But, this is not really the case, as 200 ul aliquots removed at different time points,
and replaced with same amounts of fresh 2% BSA-PBS solution, resulted in significant dilution
of the leached supernatant. At the end of 72 hrs, the amount leached for each of the meshes is
approximately two thirds of the actual amount. The graph shows that the different synthetics, with
the exception of HydrocoatT M , leach more or less the same amount of enzyme while there was no
significant difference in the leaching profile between non crosslinked (StratticeT M ) and crosslinked
(PermacolT M ) porcine dermal meshes. However, HydrocoatT M and Flex HDT M seemed to leach
very little compared to the other synthetics and biologics respectively. The hydrophilic polyurethane
coating on HydrocoatT M could lead to reduced albumin interaction with mesh surface thereby
resulting in reduced desorption of bound enzyme as compared to other synthetics. Flex HDT M
being an allograft has greater permeability for the enzyme (possibly due to more number of deep
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Figure 3.5: Turbidimetric enzyme activity assay for different lysostaphin-coated 3x3 synthetic hernia
mesh samples using a L-100 equivalent loading concentration (n=2).
seated pores) compared to porcine dermis and this could be a possible reason for the reduced leaching
[42]. Also, PariatexT M composite leached in a manner similar to the rest of the synthetics possibly
because the enzyme was adsorbed onto the polyester side of the mesh.

3.3.4

Turbidimetric lysostaphin Activity Assay
The qualitative measure of an enzymes activity is provided by the turbidimetric assay, and

this is done by monitoring the lysis of a S. aureus cell suspension; which is directly proportional to
the decrease in optical density at 600nm [80]. We monitored the decrease in optical density of a cell
suspension of O.D600 0.7 uptil 24 hrs. This was done for various meshes, shown in Figure 3.5 and
Figure 3.6, containing equivalent coatings which were obtained using the L-100 equivalent loading
concentrations. Upon comparing the rate of lysis within the first 30 mins and the optical density at
the end of 24 hrs, biological meshes exhibited a greater rate of lysis and a lower final O.D compared
to synthetic meshes indicating that they possess superior bacterial clearance properties. This may
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Figure 3.6: Turbidimetric enzyme activity assay for different lysostaphin-coated 3x3 Biological and
composite hernia mesh samples using an L-100 equivalent loading concentration (n=2)
seem rather paradoxical given that the leached enzyme is generally more for the synthetics compared
to biological meshes like StratticeT M . From the assay, it could be concluded that the initial rate of
lysis could then be attributed to the total amount of bound enzyme as against leached enzyme. This
led us to perform fractional analysis on candidate meshes to investigate if the antibacterial property
of these meshes was largely due to leached or bound enzyme activity.

3.3.5

Fractional analysis of enzyme activity
This was done to determine whether the activity of the different meshes was due to the

immobilized or leached enzyme. The assay basically compares the rates of bacterial lysis of the
supernatant, containing leached enzyme, against the total activity of the mesh which contains leached
plus bound enzyme. It is clear from Figure 3.7 that the leached enzyme activity is the dominating
factor; its contribution towards the total activity seems to be more significant in the case of the
synthetic and composite meshes, accounting for almost 90% of the mesh activity, at the end of 24
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Figure 3.7: Fraction of leached sample activity compared against total mesh activity for different
3x3 meshes at different time intervals for 24 hrs in 2% BSA.
hrs. On the other hand, biological StratticeT M showed a consistent 65% of the totally activity as due
to the leached supernatant. Interestingly, HydrocoatT M which shows minimal leaching attributes
most of its activity due to the leached enzyme and this warrants further investigation.

3.3.6

Shelf life study of lysostaphin impregnated meshes
The aim of the accelerated shelf life study was to obtain a 1 year shelf life period as this is a

crucial parameter for obtaining regulatory approval of such medical device coatings. For this purpose,
four candidate meshes-StratticeT M , BardT M , HydrocoatT M , STS PolyproT M were subjected to
lyophilization using different freezing and freezing drying protocols to optimize and retain enzyme
activity. Initially, the protocol followed for lyophilization was a 12 hrs freezing and 12 hrs freeze
drying protocol. After lyophilization, the samples were prepared as earlier mentioned and stored
at 60◦ C for 3 weeks; as this corresponds to a one year shelf life if stored at room temperature.
From Figure 3.8, Figure 3.9, Figure 3.10, Figure 3.11, it is clear that after week 1, all the meshes
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Figure 3.8: Turbidimetric lysostaphin activity assay for StratticeT M subjected to accelerated shelf
life study at 60◦ C (n=2).
were active. HydrocoatT M , as shown in Figure 3.11, showed slightly reduced enzyme activity as
evinced by the higher optical density of the cell suspension after 24 hrs compared fresh lysostaphin
impregnated HydrocoatT M . By week 2 as shown by Figure 3.10, 3.11, it was clear that both
STS PolyproT M and HydrocoatT M had lost activity, as depicted by the subsequent increase in the
optical density after 6 hrs. By week 3, shown by Figure 3.9, it was clear that even BardT M had lost
activity. Only the biological mesh Strattice TM remained active throughout the entire 3 weeks. This
suggests that the biological mesh helps in preventing thermal degradation of a heat labile enzyme
like lysostaphin and protects it by maintaining its structural conformation. These experiments lead
us to hypothesize that both the freezing time and an elevated temperature of 60◦ C had a combined
deleterious effect on the activity of enzyme coated synthetics. So, subsequent experiments using
different freezing and freeze drying protocols followed (data not shown).This lead us to an optimized
protocol for the synthetics, which included 1 hour freezing at -80◦ C followed by freeze drying for 12
hrs. The modified protocol was accompanied by a decrease in temperature for the shelf life study
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Figure 3.9: Turbidimetric lysostaphin activity assay for BardT M subjected to accelerated shelf life
study at 60◦ C (n=2).
from 60◦ C to 50◦ C and a corresponding increase in the length of the study from 3 weeks to 10 weeks
respectively. After week 1 and week 5, as depicted by Figures 3.12, 3.13, 3.14, respectively, all the
synthetic meshes seemed to show no loss in activity of the enzyme. At the end of week 6 (data not
shown), all the synthetics were active proving that any subsequent loss in activity would not be due
to packaging related issues/degradation35, since such packaging sensitive devices would exhibit a 1:2
time correlation for retention of enzyme activity at 60◦ C and 50◦ C respectively. By week 8, shown in
Figure 3.14, STS PolyproT M showed slightly reduced enzyme activity as demonstrated by the higher
optical density of the cell suspension after 24 hrs compared to fresh lysostaphin impregnated STS
PolyroT M . At the end of week 10, depicted by Figure 3.14, this seemingly gradual loss in activity
of STS PolyproT M , was confirmed wherein the enzyme coated mesh showed a final O.D similar to
the control-i.e. plain bacterial cells. Thus, we hypothesize with a fair degree of certainty that the
loss of enzyme activity during the shelf study is due to thermal denaturation of the enzyme.
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Figure 3.10: Turbidimetric lysostaphin activity assay for STS PolyproT M subjected to accelerated
shelf life study at 60◦ C (n=2).

Figure 3.11: Turbidimetric lysostaphin activity assay for HydrocoatT M subjected to accelerated
shelf life study at 60◦ C (n=2).
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Figure 3.12: Turbidimetric lysostaphin activity assay for BardT M subjected to accelerated shelf life
study at 50◦ C.(n=2)

Figure 3.13: Turbidimetric lysostaphin activity assay for HydrocoatT M subjected to accelerated
shelf life study at 50◦ C (n=2).
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Figure 3.14: Turbidimetric lysostaphin activity assay for STS PolyproT M subjected to accelerated
shelf life study at 50◦ C (n=4).

3.3.7

Retention of enzyme activity after E-beam sterilization
E beam sterilization is a well established commercial technology used in sterilizing and reduc-

ing the bioburden of medical devices. The advantage of e-beam processing over gamma irradiation
is that it results in less material degradation for several materials despite requiring similar dosage
level [163]. Two sterilization doses of 10 and 25 kGy28 were tested against enzyme coated biological
StratticeT M and synthetic BardT M as shown in Figure 3.15. The lyophilization protocol used for
preparing these meshes was a 12 hrs freezing and freeze drying protocol. Biological StratticeT M
seemed to be unaffected by the sterilization process while sterilized BardT M showed loss of enzyme
activity. However, the deleterious effect could not be attributed to e-beam sterilization as control
BardT M which was not irradiated also showed loss of activity. So, we believe that the loss in activity
could be attributed to the longer freezing time and it would be interesting to repeat this experiment
using the optimized freeze drying protocol.
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Figure 3.15: Enzyme activity testing after E-beam sterilization(10,25 KGy) of BardT M ,StratticeT M .

3.4

Discussion
According to the CDC29, nosocomial infections account for an estimated 1.7 million infec-

tions and 99,000 associated deaths each year in the US alone. Given these staggering statistics and
the policy changes with respect to reimbursement of hospital acquired infections by agencies such
as CMS(centre for medicare and Medicaid services) [129],the focus on reducing such infections has
never been greater. In this regard, a hernia mesh infection is a ubiquitous and serious complication
with incidence rates being as high as 18% [83]. S.aureus contributes to 90% of these mesh related
infections and lack of efficient strategies to tackle this unresolved issue continue to plague the use
of such prosthetic devices5. The goals of our study were two-fold; one, to come up with an antimicrobial coating for both biologic and synthetic meshes and to perform a comparative analysis of the
coating on these two classes of meshes. Our second aim was then to look at long term viability
of this coating through accelerated shelf life testing and to study the effects of sterilization and
lyophilization on this enzyme coating. To this end, we performed lysostaphin attachment onto such
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biological and synthetic meshes and compared the in vitro activity and leaching properties of these
meshes. This was done by coming up with viable and equivalent (L-50 and L-100) enzyme loading
onto the various meshes used in the study. We found that in general, synthetic meshes adsorbed
more enzyme/mg of mesh for each loading concentration compared to biological meshes but showed
possible signs of enzyme saturation at higher concentrations while the biological meshes showed a
linear adsorption isotherm. The adsorption trend is in line with studies done by various researchers
that proteins tend to prefer hydrophobic materials [121] and that globular proteins contain an increased quantity of hydrophobic residues on their surfaces which aids this interaction [63]. This is
possibly the case as lysostaphins primary structure is composed of eight tryptophan residues [63],
and these hydrophobic residues which are present on its surface probably interacts more strongly
with the hydrophobic polypropylene compared to the relatively hydrophilic polyester (PariatexT M
and polyurethane (HydrocoatT M ) surfaces. The dermal collagen present in all the biological matrices is only slightly hydrophobic and studies on collagen coated slides (ibidi GMBH Inc.) indicate
that its surface tension values are actually close to that of hydrophilic surfaces. For BardT M and
STS PolyproT M , both of which are made of monofilament knitted polypropylene, the smaller pore
size of STS Polypro

TM

possibly played a significant role, resulting in greater adsorption of the en-

zyme for the latter. With regard to the leaching profile, there was no clear trend distinguishing
the two classes of meshes. All the synthetics and biologics showed similar leaching patterns except
for HydrocoatT M and Flex HDT M . This is possibly because BSA does not interact strongly with
the hydrophilic polyurethane surface of HydrocoatT M to replace the enzyme. Allografts like Flex
HDT M , have greater permeability (due to difference in number of pores) when compared to porcine
dermis and this may result in increased enzyme retention [42]. Fractional analysis proved that the
leached enzyme was the major contributor to enzyme activity as noted by Satishkumar et al [136]
in the case of synthetics (∼90%) and to a lesser extent in the case of Strattice T M ( 65%).The above
data suggests that the biological mesh may be more active in the long term than synthetic ones, as
the bound enzyme, which is maintained in its active conformation, has a more significant contributive effect to the total activity. While the leached enzyme is extremely capable of clearing potential
bacterial loads; its long term activity could be limited by its half-life of < 1 hour in serum and a
possible 48 hrs in tissue as inferred by Kun et al [61]. However, the tissue half-life of lysostaphin is
not well studied and requires further analysis. The in vitro antimicrobial potency of such lysostaphin
impregnated meshes was demonstrated using turbidimetric assay. It was found that all the candidate
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meshes were active against the pathogenic species of interest and the biologics possessed a slightly
higher initial rate of lysis, after the first 30 mins, compared to the synthetics, possibly due to the
more significant role of the bound enzyme on the biologics during the early time points. However, its
effect is masked by the increasing amounts of leached enzyme with time. Accelerated shelf life testing
was performed on both biological and synthetic hernia meshes and a one year equivalent shelf life
was obtained for biological StratticeT M and synthetic- BardT M and STS PolyproT M . These studies
revealed that the biological mesh protects the enzyme against lyophilization and thermal denaturation; and showed no apparent loss of activity even after 3 weeks at 60◦ C.Thus it seems that biological
meshes and lysostaphin possess a symbiotic relationship, wherein the mesh protects lysostaphin and
the enzyme for its part actually improves mesh tensile strength as shown by Belyansky et al [24].
On the other hand, enzyme adsorbed onto synthetics was shown to be susceptible to low freezing
temperatures (-80◦ C) and reduced freezing time aided in preserving enzyme activity. Protein denaturation due to increased ionic strength during lyophilization in phosphate buffered systems is a
widely acknowledged problem [120] and this study shows that this issue can be overcome without the
need for stabilizers. The activity of the enzyme coated biological mesh was unaffected by the e-beam
sterilization process and in the case of synthetics, any possible deleterious effect of sterilization on
the mesh activity could not be ascertained as the optimized lyophilization protocol for synthetics
was not used. So, it would certainly be interesting to repeat this study for the synthetics using the
optimized lyophilization protocol as this would delineate the possible adverse effect of sterilization
from that of lyophilization.
While this study rightly advocates the usage of such enzyme coated meshes, certain aspects
of the study limit its conclusions. The study suffers from a lack of statiscally significant number
of samples for some of its experiments. The leaching study underestimates the actual amount of
leached enzyme due to dilution of the supernatant at each of the respective time points resulting in
a one third dilution of the final volume at the end of 72 hrs. Why allografts leach lesser amounts of
enzyme compared to xenografts needs to determined and the leaching profile of another allograftAllodermT M needs to be performed to corrobate the above fact. Also, fractional analysis studies
with other biological meshes need to be carried out to determine whether the contribution of bound
enzyme is significant in all of them or only limited to StratticeT M . Finally, the effect of lyophilization
on the meshs inherent properties needs to be studied to determine its adverse effects. In this regard,
it was observed that synthetic polypropylene meshes were more affected by lyophilization compared
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to biological meshes (picture not shown). Also, the applicability of lyophilization in stabilizing
enzyme coated biological meshes needs to be studied in detail for each mesh, as matrices that are
stabilized in buffer systems may be destabilized in vivo by this process.
In conclusion, the study demonstrated that both synthetic and biological meshes were active
against S.aureus, the pathogenic species of interest, over the desired time frame of 72 hrs within
which most hernia related nosocomial infections occur. The bactericidal effect could largely be
attributed to leached enzyme in the case of synthetics but to a lesser extent in the case of biological
StratticeT M . The long term viability of this coating was proven by performing accelerated one year
equivalent shelf life studies; with no apparent loss in enzyme activity. Also, the protective effects of
the biologic mesh against denaturation of the enzyme during processing were noted. All these results
indicate that such a peptide based coating could act as a viable alternative to currently available
antibiotic therapy in treating mesh related infections.
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Chapter 4

Antibody Directed Targeting of
Antimicrobial Copper
Nanoparticles
4.1

Introduction
The usage of copper as an antimicrobial and antifouling agent can be traced to ancient

civilizations such as the Greeks and Indians, who used copper vessels to store water because of its
bacteriostatic properties and the Phoenicians who used copper for their ship hulls to thwart fouling
[32]. In recent history, Japanese soldiers, during World War II, immersed pieces of copper in their
bottles to prevent dysentery and NASA initially designed sterilization systems for their Apollo flights
using copper and silver [7].
Usage of Copper in medical devices and wound healing also has a long history through the
sustained use of copper uterine devices by women [19], [30], [59] and its use by various Saharan
tribes and the Aztecs in treating foot sores and wound infections [32]. The exponential increase
of nosocomial infections and the lack of viable alternatives in treating drug/antibiotic resistant
microbes, have led to the resurgence of heavy metal usage, mainly silver and copper, in the fight
against infections.In this regard, copper has proven to be effective not only against both gram positive
and gram negative bacteria but also against super bugs like Methicillin-resistant Staphylococcus
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aureus (MRSA) and Vancomycin-resistant enterococcus (VRE) [5].The broad spectrum activity of
copper can be attributed to the various mechanisms by which copper exerts its antimicrobial effects.
It has been shown that copper substitutes other native metals through ligand interactions. In this
regard, coppers strong affinity for thiol groups and oxygen enables it to perform the above mentioned
roles. Also, copper being a redox active metal, produces highly reactive hydroxyl radicals which in
turn damage lipids, proteins, DNA and other biomolecules, thus contributing to its inherent toxicity.
Hence, possible coating applications of such bactericidal metallic nanoparticles onto medical devices
and instruments can be envisioned, wherein they play an effective role in preventing nosocomial
infections [132].
In recent times, the usage of silver as an antimicrobial agent has gained popularity and
nanocrystalline silver dressings like ActicoatT M (Convatech Inc) have ushered in an era, wherein
antimicrobial silver nanoparticles, incorporated into topical formulations is being advocated .This
has occurred as silver compounds, viz., silver nitrate and silver sulfadiazine, may get deactivated by
anions in blood or cause cosmetic abnormalities like agyria [81]. However, the possible cytotoxicity
and unforeseen deleterious effects on the body and the environment make the usage of such nanoparticles a contentious issue. Despite these risks, the benefits far outweigh the concerns, and hence there
has been a lot of interest and work in this area. In March 2008, the USA Environmental Protection
Agency (EPA) approved copper as an antimicrobial agent (Copper development Association Inc.)
to reduce specific harmful bacteria related to possibly lethal microbial infections. Also, a few studies
have reported the antimicrobial properties of copper nanoparticles and the significant promise they
possess as bactericidal agents [57], [112]. Interestingly, copper possesses significant wound healing
properties and hence copper-based therapeutics represents a viable approach to promote dermal
wound healing [11] unlike silver which has often shown to hinder or delay the wound healing process
[18]. Copper has shown to affect various stages of wound healing by inducing VEGF and integrin
expression besides bringing about fibronectin stabilization. Also, in the presence of copper, upregulation of enzymes like metallothioneins and lysyl oxidases takes place thus causing increased cell
proliferation, re epithelization and improved matrix remodeling [21].
Thus, this study basically looks at the antimicrobial efficacy of antibody directed targeting of copper nanoparticles against two clinically relevant wound infection pathogens-gram positive
S.aureus and gram negative P.aeruginosa, both of which pose considerable challenges to clinicians.
The goal of the antibody directed targeting was two-fold- i) to see if there was specificity in bacterial
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targeting and ii) to reduce the working concentration of these nanoparticles thereby possibly alleviating the potential dermal toxicity issues associated with their usage in wound healing materials.

4.2

Materials and Methods
Preceptrol cultures of S.aureus (ATCC# 27660) and two strains of P.aeruginosa (ATCC#10145-

U, ATCC# 10145) were obtained from American Type Culture Collection (Manassas, VA).Polyclonal
rabbit IgG antibodies against S.aureus (Catalog No: 6881), P.aeruginosa (Catalog No: 3701) and
mouse monoclonal Ab IgG 1 antibody against Lipotechoic acids (Catalog No: 3801) found in S.aureus
were obtained from Virostat Inc. (Portland, ME) and stored at -20◦ C. Microsep Centrifugal Devices
with a modified Polyethersulfone membrane (low protein binding; MWCO - 30K) used for antibody
purification from azide were purchased from Pall Life Sciences (Ann Arbor, MI), BBL Trypticase
Soy Broth(Pancreatic Digest of Casein 17.0 g, Papaic Digest of Soybean 3.0 g, Sodium Chloride 5.0
g, Dipotassium Phosphate 2.5 g, Dextrose 2.5 g), Mueller Hinton Broth for antimicrobial susceptibility testing (Acid hydrolysate of casein 17.5g, Beef extract 3.0g,starch 1.5g) and Difco Nutrient
Broth were all obtained from Becton and Dickinson (NJ, U.S.A).Laboratory grade purified Agar and
L-shaped cell spreaders was obtained from Fischer (Houston, TX). MTT based In-vitro cytotoxicity
kit was purchased from Sigma Aldrich (St. Louis, MO) and Polyacrylic acid (PAA) of molecular
weights 5000 and 2000 Daltons were used in nanoparticle preparation (Dr. Chumanovs Lab, Dept.
of chemistry).

4.2.1

Copper Nanoparticle Preparation
Copper nanoparticles (CuNPs) were synthesized using solution of copper (I) oxide stabilized

with poly (acrylic acid). To the copper solution, a small amount of sodium borohydride was added to
reduce the copper forming the small nanoparticles. The synthesized nanoparticles were then purified
by centrifugation at 30,000g and resuspended thrice in deionized (DI) water to remove unreacted
sodium borohydride and other possible contaminants.

4.2.2

Antibody attachment to the nanoparticles
The received polyclonal and monoclonal antibodies (Ab) were purified by centrifuging the

required antibody aliquots using a 30K microsep for 25 mins at 3500g before performing the antibody
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attachment to the nanoparticles. This was done to remove the azide, which is bactericidal by
itself. Different initial nanoparticle to antibody ratios of 1:10(150 ul of 5 mg/ml Ab added to 1
ml DI water solution containing 12 ppm CuNPs), 1:1(150ul of 5 mg/ml Ab added to 1 ml DI
water solution containing 120ppm Cu NPs), 10:1(15 ul of 5 mg/ml Ab added to 1.135 ml DI water
solution containing 120 ppm Cu NPs) were then obtained for both the types of polyclonal antibodiesi.e. anti S.aureus Ab and anti-Pseudomonas Ab; by physical adsorption of the antibody onto the
nanoparticles at 370 C for 10 hrs in an incubator with minimal shaking(100rpm). In the case of the
monoclonal IgG 1 Ab, 150 ul of 100ug/ml antibody solution was added to 1 ml of DI water containing
120 ppm Cu NPs, resulting in a 50:1 nanoparticle: antibody solution. After adsorption, the coppernanoparticle conjugates were spun down at 30,000g for 1 hour to remove unbound antibody from the
supernatant and redispersed. This process was repeated twice to make sure that unbound antibody
was removed effectively.

4.2.3

Determining Binding yield using fluorescently labeled Antibody
Fluorescent labeling of the polyclonal and monoclonal antibodies was done using Alexa

Fluor 594 dye due to its improved resistance to photo bleaching [26]. Approximately 5 g of Alexa
Fluor 594 ( 73,000) was dissolved in 500 L of dimethylformamide; and 20 L of the dye was added
to 150ul of a 5 mg or 0.5 mg /ml solution of the polyclonal antibodies and 150 ul of 100ug/ml of
monoclonal IgG 1 antibody. The antibodies were incubated for two hours with the dye at 37◦ C,
and centrifuged for 25 mins at 3,500 g using a MicroSep (MWCO 30K) to remove any unbound
dye and azide; followed by resuspension of the labeled enzyme in DI water, thereby maintaining the
initial volume. It was then added to nanoparticles of 120 ppm/12 ppm to generate two different
initial ratios of 1:1, 10:1 of fluorescently labeled antibody-nanoparticle conjugates as mentioned
above. The same purification procedure enlisted above was followed to remove unbound antibody
and the flourescence (Ex: 594, Em: 625) was measured using a microplate reader. Binding % of
these conjugates was determined by adding the individual flourescence of the initial supernatant
with both the wash supernatants; followed by subtraction of this combined value from the initial
flourescence of the nanoparticle-antibody conjugates. The calculation used for determining the
amount of bound antibody molecules for the varying ratios is determined after calculating the initial
number of antibody molecules in the system and the binding %. In this regard, Dimensions of Ab
are 12.5*10*5 (length*breadth*height) and molecular weight of Ab =150K Da. Number of antibody
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molecules in a 100 ug/ml and 5 mg/ml solution are =4*1014 and 20*1015 respectively. For e.g, if
binding% is 5% for an initial 150 ul Ab solution of 5mg/ml, then total number of bound antibody
molecules is 1.5* 1014 molecules.

4.2.4

Characterization of plain Copper and Copper-Antibody nanoparticle conjugates

4.2.4.1

Particle size and Zeta potential Analysis
Particle size and zeta potential analysis of the synthesized nanoparticles was performed to

determine the size distribution and colloidal stability respectively. Eppendorfs containing copper
nanoparticles suspended in DI water were sonicated for 10 min. 300ul of the 120ppm CuNPs solution
was then transferred into cuvettes and DI water was used to fill it up to the marked level. For zeta
potential analysis, 100 ul of 120 ppm copper nanoparticles was added to 300ul of DI water and
the measuring electrode was inserted into this solution. The particle size and zeta potential was
obtained by dynamic light scattering with a 90Plus particle size /zeta potential analyzer (Brookhaven
Instruments Corporation, Holtsville, NY).For size measurements, the polydispersity index (PDI)
was maintained at 0.20.3 in all the experiments to ensure proper dispersion. Particle size and zeta
potential was expressed as a combined mean diameter and zeta potential in nm and mV (+/- SD)
respectively.

4.2.4.2

UV-vis Spectroscopy and Transmission Electron Microscopy
The synthesized nanoparticles were characterized by UV-vis spectroscopy (Bio-Tek Instru-

ments, Inc., Winooski, VT, USA) and high resolution transmission electron microscopy (Philips,
Holland CM 200) was done at the Electron microscopy facility at the Advanced Materials Research
Laboratory (Pendleton, SC).

4.2.4.3

Determining the optimum nanoparticle: antibody ratio for bacterial targeting
The idea behind this experiment was to optimize the nanoparticle concentration and deter-

mining the most suitable nanoparticle: bound antibody ratio that would result in maximal targeting
of the bacterial cells. Three different initial ratios (10:1, 1:1, 1:10) of nanoparticle and polyclonal
antibody solutions were mixed as mentioned in Section 4.2.2. The antibodies in these conjugates
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were fluorescently tagged with Alexa Fluor 594 dye as discussed in the section above. Theoretical
calculations on determining the concentration required for monolayer and multilayer coverage of the
bacterial surface was determined as shown below:
Dimensions of P.A =0.55 um (diameter) by 1-1.2 um length. Dimensions of S.A= 1 um
(spherical) Surface area of P.A=2r (r+h) =3.14*0.55(1.1+0.275) =2.374*10-12 m2 =2374 nm2 Surface area of S.A=4r2= 4*3.14*0.5*0.5=3140nm2 . Surface area of 1 nanoparticle covering the bacterial surface=d2 = 2 nm*2 nm=4 nm2 No of nanoparticles required to cover 8*1011 cfu/ml of P.A =
(2374*8*1011 )/4 =4748*1011 nanoparticles. No of nanoparticles required to cover 8*1011 cfu/ml of
S.A= (3140*8*1011 ) /4 = 6280*1011 nanoparticles. Now no. of nanoparticles in 1 ml (120 ppm or
ug/ml) solution= 3.21*1015 .
So we can see that there would be a monolayer for P.A or half a monolayer concentration
for S.A in the case of 1:10 ratio and a 10 times monolayer concentration for P.A and ∼ 5 times a
monolayer nanoparticle concentration for S.A in the 1:1 and 10:1 system.
For this purpose, 500 ul of these solutions containing the respective Ab was added to 500 ul
of S.A and P.A cultures containing ∼ 8*101 1 cfu/ml. Three controls were used-1) 500 ul of 120ug/ml
plain copper nanoparticles added to 500 ul of the above bacterial suspension. 2) 75 ul (as in the
case of 1:10,1:1 ratio)/ 15ul(as in the case of 10:1) of 5mg/ml polyclonal Ab added to 500 ul of the
bacterial suspension and made upto 1 ml using DI water.3) 500 ul of bacterial suspension added to
500 ul of DI water.
The cells were incubated with these solutions for 1:30 hrs before spinning down at 1200rpm
so that only bacterial cells spin down along with the bound nanoparticle-antibody conjugates. 200 ul
aliquots of these samples and controls, and supernatant after spinning down of bacterial cells, were
used for simultaneous flourescence measurements (Ex: 594. Em: 625) and read using a microplate
reader. The flourescence measurement of the samples was normalized after subtracting the flourescence contribution due to plain nanoparticle-bacterial cells interaction, before and after spinning
down. The difference in flourescence before and after spinning down was determined and used for
calculating the binding% for each of these ratios.

4.2.5

Cultivation of Microorganisms
The Preceptrol vials containing pelleted cultures from ATCC were opened according to

instructions and 2ml of Trypticase Soy broth prepared according to manufacturers instructions was
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added to dissolve the pellet by pipetting it vigorously. 200 ul of this bacterial suspension was added
to 15 ml sterile test tubes containing Trypticase Soy Broth for cultivating S.aureus or Difco Nutrient
Broth for cultivating P.aeruginosa. The test tubes were then gently shaken in an incubator at 37◦ C
for 24 hrs to achieve mid log phase growth which was obtained by taking aliquots at different time
points to obtain a growth curve. The test tubes were then stored in the freezer at - 20◦ C if not used
immediately for experiments. Before using frozen cultures for experiments, they were thawed and
incubated at 37◦ C for 24 hrs to monitor their growth curve. From the growth curve, time taken for
mid log phase to be reached was observed and the freshly thawed cultures were then incubated for
this specified period (generally around 18-24 hrs) to obtain a similar mid log phase.

4.2.6

Determination of minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC)
The minimum inhibitory concentration (MIC) assay ascertains the concentration of a drug

that impedes the visual growth of a microorganism in a dened nutrient broth. MBC is formally
dened as the concentration of test agent that kills 99.9% (3 log10 CFU/ml) of the microorganism
within a specied period of time, usually measured after 24 hr of growth [110]. For this purpose,
freshly prepared mid log phase cultures of S.aureus and P.aeruginosa and cation adjusted Mueller
Hinton broth was used for antimicrobial susceptibility testing. 100 ul of freshly prepared broth
was added to a sterile 96 well plate and 100 ul of nanoparticle-antibody conjugates which were
of two types- antigen specific and antigen non-specific antibody, were tested and their MICs were
compared against plain Cu NPs and specific Ab without nanoparticles. Plain bacterial cells without
the nanoparticles were used as control. In a 96 well plate, row wise two fold serial dilution of
polyclonal P. Ab and S. Ab conjugated copper nanoparticles was carried out starting with an initial
concentration of 600ug/ml when tested against P.aeruginosa. This was done in triplicates per test
sample. Against S.aureus, the tested concentration range of the conjugates was from 900 to 300ug/ml
and was done in triplicates as mentioned above. Plain copper nanoparticles were ultrasonicated for
10 mins in a water bath and then tested in a concentration range of 600-2800 ug/ml against both
the types of bacteria. The specific Ab was tested against the targeted species by serially diluting
it from a concentration of 1mg/ml. Two different initial ratios of nanoparticle: antibody, 1:1 and
10:1 was tested for the antibody-nanoparticles conjugates at the above concentration against both
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the types of bacteria. To the final volume of 100ul in each well, 5 ul of a cell suspension containing
approximately 35*107 cfu/ml and 61*107 cfu/ml of P.aeruginosa and S.aureus respectively was added
to each well and to the controls. The 96 well plates were then sealed with sealing tape and wrapped
in a polyethylene cover before being placed in the incubator for 18 hrs at 37◦ C.At the end of 18 hrs,
the absorbance was measured at 600nm and compared against controls. The lowest concentration at
which no visual turbidity could be observed and correspondingly showed an absorbance value one
third of the control was taken as the MIC for the tested sample. The 96 well plates were then placed
back immediately, retaped and incubated for another 6 hrs before removing 100ul from each of the
well that showed no visible growth in the MIC assay. These were then plated on agar plates using
L-shaped spreaders and inverted for 24 hrs at 37◦ C. After 24 hrs, the concentration that produced
a ≥ 3 log reduction was determined as the MBC.

4.2.7

MTT Cell Proliferation Assay
Measurement of cell viability and proliferation is an integral aspect of assessing a cell pop-

ulations response to external factors in many in vitro assays [138].In this regard, the reduction of
tetrazolium salts is widely acclaimed as a dependable method of examining cell proliferation. The
yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) is reduced
by the presence of dehydrogenase enzymes in metabolically active cells, to produce reduced compounds such as NADH and NADPH. The subsequent intracellular purple formazan that is formed;
should be solubilized and quantified by spectrophotometric means [46]. The MTT cell proliferation
assay deals with the cell proliferation rate, and conversely, reduction in cell viability due to apoptosis
or necrosis.
Mouse 3T3 fibroblasts (donated by Cassie Gregory; Department of Bioengineering, Clemson University) were previously cultured in Cell culture flasks in DMEM supplemented with 1%
Fetal Bovine Serum (FBS) and 1% antibiotic (Penicillin/Streptomycin). The cells were trypsinized,
centrifuged for 5 minutes at 1000 rpm, aspirated and resuspended in fresh media. The cell density
was adjusted to 2.5*105 cells/ml and 1 ml of this cell suspension was plated into individual wells
of a 12-well plate with fresh media and allowed to attach to the bottom and grow to confluence for
24 h at 37◦ C in a humidified 5% CO2 environment.. The next day, 1 ml of the media containing
plain copper nanoparticles in three different concentrations- 1200, 120, 12 ppm and nanoparticleantibody conjugates in two different ratios (1:1 and 10:1) both containing 120 ppm concentration of
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nanoparticles (used in MIC studies) were added in triplicates to each well of the column of a 12 well
plate. Cells in media were used as negative controls. The cells were incubated for 60 h at 37◦ C in
a humidified 5% CO2 environment. Cell viability was routinely checked under a microscope during
the stipulated time period. After 60hrs, the media containing 0.5 mg/ml MTT solution (prepared
from a stock of 5mg/ml) was added to 1 ml of fresh media and the plate was incubated at 37◦ C for 4
h in a humidified, 5% CO2 atmosphere. After 4 hrs, the media was removed and DMSO was added
and pipetted up and down to solubilize the MTT formazan crystals. The well plates were then read
at 590 nm and % viability was calculated by taking the ratio of the absorbance of the test sample
at 590nm to the absorbance of the control (plain cells without drug).

4.3
4.3.1

Results and Discussion
Synthesis of Copper Nanoparticles
The synthesized copper nanoparticles were stabilized with polyacrylic acid (PAA) as a cap-

ping agent and were well dispersed in DI water at a concentration of 120 ppm. The nanoparticles
possess a distinct green coloured appearance when freshly prepared and two different molecular
weights of PAA-5000Daltons and 2000 Daltons were tested to see if molecular weight of the polyelectrolyte had any effect on the size of synthesized nanoparticles [159]. Concentrating the nanoparticles
to concentrations 600ug/ml was followed by ultrasonication for 10 mins in a water bath, resulting
in stable suspensions when used within a timeframe of 10 hours of concentrating them. Also, highly
concentrated nanoparticle solutions ( 600 ug/ml) resulted in an apparent increase in viscosity of
the solution. Storage of nanoparticles for more than 5 days showed considerable dimming of the
green coloration possibly due to oxidation despite being stored in tightly closed glass vials (shown
in Figure 4.1 below).

4.3.2

Antibody attachment to nanoparticles
The antibody was immobilized onto the copper nanoparticles by physical adsorption. Chemi-

cal crosslinking of the antibody onto the nanoparticles was tried using EDC (1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide) as a crosslinker and 2-mercaptoethanol as a quencher, followed by centrifugation
through a 10KDa membrane to remove the excess EDC. However, this resulted in huge aggregation
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Figure 4.1: Dim green colouration of copper nanoparticles due to oxidation.
of nanoparticles and hence chemical immobilization of the antibody was not pursued. Purification
of the adsorbed antibody was done by centrifugation at 30,000g to remove unbound antibody and
to prevent loss of copper nanoparticles during this process. This was repeated thrice to make sure
that unbound antibody was removed.

4.3.3

Binding yield of Antibody on Nanoparticles
The binding yield of two different ratios of antibody-nanoparticle conjugates are enlisted

in Table 4.1. Lowering the nanoparticle: antibody ratio from 10:1 to 1:1 showed increased binding
as expected. For polyclonal P.A Ab-CuNP-5000 conjugates, the total amount of bound antibody
molecules increased by 5times when incubated with a 10 fold greater concentration of antibody in
the 1:1 ratio when compared to the 10:1 ratio. The data confirmed the hypothesis that increasing
the antibody concentration while maintaining a fixed concentration of nanoparticles would increase
nanoparticle-antibody interaction. In the case of polyclonal S.A Ab-Cu NP-5000 conjugates, the
lower 1:1 ratio showed that the total amount of bound antibody was ∼ 9 times greater than in the
10:1 ratio. The binding % for 150ul of monoclonal S.A antibody onto 1 ml of 120ppm nanoparticle
was 23.25%, much greater than the binding% of 8.74% for the corresponding 150 ul of polyclonal
S. Ab antibody. However, this comparison can be rather misleading as the monoclonal antibody
solution concentration was 100ug/ml compared to a much higher concentration of 5 mg/ml of its
polyclonal counterpart. However, this does hint towards an important point, that an optimum
initial antibody: nanoparticle concentration needs to be established for different antibodies, so as
to improve the possibility of an antibody-nanoparticle interaction as against the seemingly more
favoured antibody-antibody/nanoparticle-nanoparticle interaction. Given that the base area of the
antibody is around 120nm2 and assuming that surface area covered by one nanoparticle when bound
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Type of antibody (Initial nanoparticle: antibody ratio)

Binding%

S.D

Ratio
between
nanoparticle:
bound antibody

0.7911

Total number of bound
antibody
molecules
1.6*101̂3

Polyclonal P.A
(10:1 ratio)
Polyclonal P.A Ab
1 ratio)
Polyclonal S.A
(10:1 ratio)
Polyclonal S.A
(1:1)
Monoclonal S.A
(50:1)

Ab

5.65%(n=3)

(1:

2.409%(n=2)

0.0918

7.5*101̂3

38:1

Ab

10.88%(n=3)

0.69

3.2*101̂3

100:1

Ab

8.743(n=2)

0.1935

2.61*101̂4

12:1

Ab

23.25%

1.4*101̂3

228:1

200:1

Table 4.1: Antibody Binding yield and resultant antibody: nanoparticle ratio

to an antibody is d2 and therefore ∼ 4 nm, there could be a possibility that each antibody; could
theoretically bind a few nanoparticles per antibody molecule.
Note: The study makes an assumption that no copper nanoparticles are lost during the
purification process.

4.3.4

Characterization of plain Copper and Copper-Antibody nanoparticle conjugates

4.3.4.1

Particle size and zeta potential analysis
Particle size distribution of the copper nanoparticles capped with PAA-5000, averaged over

two independent experiments, showed that there was a trimodal distribution of copper nanoparticles
with particles predominantly in the size range of 1-3nm and very small fractions of 25-40 nm, and
100-120nm.The mean diameter of this predominant fraction of nanoparticles capped with PAA-5000
was shown to be 2.1 nm. The attachment of polyclonal P.A Ab and S.A Ab resulted in an increase
in mean diameter of the plain copper nanoparticle as shown in Table 4.2.It is important to note that
the concentration of the antibody used for these measurements was equivalent to the concentration
required to achieve an initial 10:1 nanoparticle: antibody ratio mentioned in section 4.2.2.
This significant increase in nanoparticle size is suggestive of the fact that addition of antibody possibly leads to its attachment and/or aggregation of nanoparticles. For, plain copper
nanoparticles capped with PAA of a lesser molecular weight i.e. 2000 Da, the predominant frac53

Sample
Plain CuNP-PAA 5000
Plain Cu NP-PAA
2000
Cu NP-P. Ab 5000
Cu NP-S. Ab 5000
Cu NP-P.AB 2000
Cu NP-S. Ab 2000

Mean diameter (nm)
2.1
16.52
74.12
60.12
106.52
118.5

S.D
1
2.5

Zeta Potential(mV)
-48.5
-36.16

S.D
4.25
4.65

25.62
28.2
30.3
23.5

-33.80
-42.3
-8.48
-12.44

12.3
20.3
3.57
4.03

Table 4.2: Sizing and zeta potential analysis of copper nanoparticles and its conjugates

tion showed an increase in particle size from 1-3 nm to 14-19 nm. Increasing the concentration of
PAA should result in a more pronounced coating and therefore the noted increase in size of the
nanoparticles capped with PAA-2000 could be attributed to this fact as amount of polymer added
was determined by its weight. An increase in size of such PAA-2000 capped nanoparticle-antibody
conjugates was also noted as shown in Table 4.1.
Zeta potential studies were performed to characterize electrostatic properties of colloidal
suspensions used in this study. Table 4.4 shows zeta potential values averaged over two independent
experiments for each of the samples. The plain copper nanoparticles capped with PAA of both
molecular weights resulted in a largely negative zeta potential as expected (shown in table 4.1).However, the nanoparticle-antibody conjugates capped with PAA-2000 showed a zeta potential around
-10mV suggesting that the sample would be unstable at higher concentrations, compared to conjugates coated with PAA-5000 which showed highly negative zeta potential indicating stability of these
conjugates. It is presently unclear why PAA-2000 coated nanoparticle-antibody conjugates showed
significantly lesser zeta potential and this finding was also complimented by the fact that there was
increased difficulty in resuspending these conjugates after centrifugation during purification. Hence,
these copper nanoparticle capped with PAA 2000 were discarded for our further experiments.

4.3.4.2

UV-vis Spectroscopy and Transmission Electron Microscopy
The UV/Vis absorption spectra of copper nanoparticles capped with PAA-500 that were

synthesized displayed a well-defined absorption peak at around 590 nm as against 570 nm described
in literature [159], [60] (Figure 4.2). The absorption peak at 570 nm can be attributed to the
excitation of plasmon resonance or interband transition, which is a characteristic property of the
metallic nature of copper nanoparticles. The appearance of the 590 nm absorption peak indicates
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Figure 4.2: UV/Vis Spectra of Copper Nanoparticles. Image courtesy of Whitney Synder in
Dr.G.Chumanovs Lab, Dept. of Chemistry, Clemson University.
that although reduction of copper (I) oxide to copper nanoparticles may take place under during the
preparation phase, which is in basic pH, there is almost immediate oxidation when transferred into
DI water ( neutral pH), and this possibly causes a shift in the absorption peak. Also with time,
the copper plasmon bands near 590 nm shows broadening and tailing toward longer wavelengths
(not shown). This red-shifting plasmon bands indicate that aggregates are presented as the result of
oxidation which is corroborated by the corresponding dimming of the dark green colouration of these
nanoparticles. Thus, all of this suggests that our nanoparticles are transformed into CuO/Cu2O
nanoparticles rather than remaining as copper nanoparticles.
The size of the copper nanoparticles capped with PAA-5000 as determined by TEM analysis demonstrated that copper nanoparticles exhibited a spherical appearance with no sharp edges
observed (Figure 4.3. The particle size measurements via TEM ranged from 7.908.5 nm for the
predominant fraction as against the 2.1 nm estimation by DLS, and some of the larger aggregates
were shown to be around 15 nm.

4.3.5

Determining the optimum nanoparticle: antibody ratio for bacterial targeting
It is clear from Table 4.3 that the initial nanoparticle: antibody ratio of 1:1 produced the

best binding results when compared to the 1:10 and 10:1 initial ratios. It seems that a combination
of greater than monolayer nanoparticle concentration (5 times the monolayer for S.A and 10 times
for P.A)
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Figure 4.3: TEM of the plain Cu-NPs at 500X. Image courtesy of Whitney Synder in
Dr.G.Chumanovs Lab, Dept. of Chemistry, Clemson University.

Sample (P.Ab: Cu NPs)

1:10 ratio (P.A)
1:1 ratio (P.A)
10: 1 ratio (P.A)
Np-bacteria
(control)
(P.A)
75ul P.Ab-bacteria (P.A)
(no nanoparticles)
15ul P.Ab-bacteria (P.A)
(no nanoparticles)
plain bacteria cells (P.A)
Sample (S.Ab:
Cu
NPs)
1:10 ratio (S.A)
1:1 ratio (S.A)
10:1 ratio (S.A)
Np-Bacteria control (S.A)
75ul S.A Ab-bacteria(S.A)
(no nanoparticles)
Plain bacteria (S.A)

Initial Flourescence
Before
spinning down
the cells
1395
1007
220
105

Flourescence
of supernatant
after spinning
down the cells
1367
881
227
75

Binding%

18094

17487

3.35

1961

1899

3.16

81

78

1140
902
476
116
14524

1081
788
459
94
13544

101

81

No attachment
10.643
No attachment

3.61
11.70
No attachment
6.74

Table 4.3: Optimal Antibody: Nanoparticle Ratio for Bacterial Targeting
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and an optimal bound antibody: nanoparticle ratio of 1:12 and 1:38 for S.A Ab and P.A
Ab respectively, produced the best targeting results. It was determined experimentally that bacterial suspension and copper nanoparticles by themselves do not produce a large background signal;
however, negative binding measurements for some ratios suggest that there is a quenching of initial
flourescence of the antibody due to the presence and interaction of nanoparticles and bacterial cells
with the antibody. Also, the relatively low binding yield of 3-3.5% in the control containing only
antibody and bacterial cells, suggests that 1:30 hrs incubation was not sufficient enough time for
the binding equilibrium (KD) to be established and longer incubation time was probably required.
Another reason for the poor binding data of this control could be due to the earlier mentioned fact
that an optimum working concentration of the antibody needs to be established, for it to perform
its role effectively.However, importantly no conclusion coud be derived from this experiment as the
binding% was within the error of the experiment.

4.3.6

Cultivation of Microorganisms
The ATCC preceptrol cultures of both S.aureus and P.aeruginosa showed loss of cell viability

after two passages, when stored in broth solutions at -20◦ C for a period of more than three weeks
before the next passage. Loss of cell viability is an established concern that needs to be addressed by
proper storage techniques and frequent passaging [123]. This effect was quite markedly observable
for S.aureus, which is relatively a slower growing strain compared to P.aeruginosa. Antimicrobial
studies carried out using such cultures gave false positive results which were not reproducible when
the same experiments using fresh cultures were repeated. Subsequently, fresh passaging of cells was
carried out every tenth day and careful attention was paid to comparing the growth curves of freshly
passaged cells from the primary culture, and that of the thawed culture from subsequent passages,
before usage. All antimicrobial studies were completed within 3 passages of a freshly ordered culture
to negate any issues related to loss of cell viability.

4.3.7

Determination of minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC)
MIC experiments were carried out against P.aeruginosa and S.aureus using two types of

nanoparticle-antibody conjugates consisting of a specific antibody and a non-specific antibody to
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verify the specificity of antibody directed targeting. The MICs of these conjugates was compared
against copper nanoparticles and the specific antibody without nanoparticles. The MICs for the
samples and controls against S.aureus and P.aeruginosa are enlisted in Table 4.4. Higher MICs were
recorded for S.aureus when compared to P. aeruginosa, for these nanoparticle and nanoparticleantibody conjugates. This suggests that gram negative P.aeruginosa is more susceptible to these
copper nanoparticles than gram positive S.aureus. The few studies conducted to compare susceptibility of gram positive and gram negative to metallic nanoparticles show contradictions and this is
due to the fact that most generalizations are made using one particular member of both the classes,
which is generally not sufficient to make such a sweeping statement. The MBC values reported
here are closer to the MBC values reported by G. Ren et.al for CuO and Cu2O nanoparticles as
against plain Cu nanoparticles. However, the size of the nanoparticles used in that study was 60
nm similar to the size of the nanoparticle-antibody conjugates but much larger than the 2nm size
of the bare copper nanoparticles used in the present study. The present study also shows quite
a large variation in MIC and MBCs between the two different strains of P.aeruginosa and this is
once again in agreement with the above reported study, which showed great variations in MBCs between two different strains of the same species of S.aureus. The MICs of the nanoparticle-antibody
conjugates against P.aeruginosa, in the 10:1 and 1:1 ratio, is 3 times and 6 times lesser than that
of plain nanoparticles. This corroborates with the earlier findings in section 3.5, that the initial
nanoparticle: antibody ratio of 1:1 ratio is the most optimal one for targeting. However, varying the
nanoparticle: antibody ratio did not have its intended effect on the MICs against S.aureus. Also,
the antibodys effect was less pronounced for S.aureus as against P.aeruginosa. While the results
point towards a possible role played by the antibody in improving bacterial targeting, it is currently
not clear why the non-specific antibody produces the same effect as that of the specific antibody.
It is hypothesized that the antibody containing a few bound nanoparticles per antibody molecule
causes a local increase in the nanoparticle concentration when in contact with bacteria cells and this
seems to be a random event rather than a result of strong antibody-antigen interaction. Also the
beneficial effect of the antibody-nanoparticle conjugates for both the tested species and especially
for P.aeruginosa; seems to be limited to improving the bacteriostatic properties at lower nanoparticle
concentrations (shown by reduced MICs) rather than contributing significantly to its bactericidal
properties (denoted by comparable MBCs between conjugates and bare nanoparticles).This result
proves that although bacterial growth may be inhibited due presence of copper when encountered
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Sample type
Plain NP against P.A 10145
Cu NP-P.A Ab (ratio 1:1) against P.A-10145
Cu NP-P.A Ab (ratio 10:1) against P.A -10145
Cu NP-S.A Ab(ratio 1:1) against P.A-10145
Cu NP-S.A Ab (ratio 10:1) against 10145
Cu NP- S.A monoclonal Ab(ratio 50:1)
against P.A-10145
Plain Cu NP against P.A 10145-U
Cu NP-P.A Ab(10:1) against P.A 10145-U
Cu NP-S.A Ab (10:1) against P.A 10145-U
Plain Ab without nanoparticles against
P.A.10145-U
Plain P. Ab without nanoparticles against
P.A-10145
Plain NP against S.A
Cu NP-S.A Ab against S.A (ratio of 10:1)
Cu NP-S.A Ab against S.A(ratio of 1:1)
Cu NP-S.A Monoclonal Ab against S.A(ratio
of 50:1)
Cu NP-P. Ab against S.A (ratio 10:1)
Cu NP- P. Ab against S.A (ratio 1:1)
Plain Ab against S.A

MIC (ug/ml)
900(n=3)
150(n=3)
300(n=3)
150(n=3)
300(n=3)
300(n=3)

MBC(ug/ml)
1800(n=3)
1500(n=3)
1500(n=3)
1500(n=3)
1500(n=3)
did not test

600(n=5)
60(n=5)
60(n=5)
250(n=2)

900(n=2)
600(n=2)
600(n=2)
does not kill bacteria at 1 mg/ml
does not kill bacteria at 1 mg/ml
2800(n=2)
2800(n=3)
2400(n=3)
2400(n=3)

550(n=2)
1200(n=2)
720( n=3)
720(n=3)
720(n=3)
720(n=3)
720(n=3)
1mg/ml(n=2)

2800(N=3)
2400(n=3)
Does not kill bacteria at 1 mg/ML

Table 4.4: MIC (ug/ml) and MBC (ug/ml) of Copper nanoparticle using different antibody:
nanoparticle ratios.

initially, they may possess enough mechanisms with time; such as DNA repair, reduced sensitivity
through mutations, copper resistant pathways and cellular components; to combat its toxicity unless
the metal concentration is the MBC value, beyond which they succumb.

4.3.8

MTT Cell proliferation assay
Assessing cellular response is necessary for determining the prospective biomaterials inherent

cytotoxicity.3T3 Fibroblasts were chosen as an appropriate cell model as they play a crucial role
in the inflammatory response and in wound healing. This study aimed to evaluate the cellular
response to copper nanoparticles and the nanoparticle-antibody conjugates. While a few studies have
evaluated the antimicrobial nature of these copper nanoparticles, none of them have actually looked
at cytotoxicity of such nanoparticles, especially in a relevant cell line like the 3T3 fibroblasts. Since
the study ultimately envisions using such antimicrobial copper nanoparticles for dermal applications
and given coppers therapeutic potential in wound healing; this assay would provide a good starting
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point for evaluating its actual suitability for such applications.
The results for the MTT assay are provided in Figure 4.4.The two relevant initial nanoparticle: antibody ratio of 1:1 and 10:1 for P.Ab, containing nanoparticles at a concentration of 120
ppm, were evaluated along with three different concentrations of copper nanoparticles (1200ppm,
120ppm, 12ppm) and an appropriate control consisting of plain cells without any nanoparticles. The
MTT assay was performed after 60 hrs of incubation with these nanoparticles. Cell viability was
plotted for the various nanoparticles/nanoparticle-antibody conjugates.
It is quite clear, that the relevant concentration of 120ppm and above, for both nanoparticle
and nanoparticle-antibody conjugates, were extremely cytotoxic resulting in less than 5% cell viability. Nanoparticles at a concentration of 60ppm also showed only 20% cell viability (data not shown).
Only nanoparticles at a concentration of 12ppm, showed a healthy 82% cell viability but given the
MIC and MBC data, this concentration of nanoparticles is incapable of clearing even a moderate
inoculum of 105 -106 cfu/ml. Thus, these nanoparticles seem to be more cytotoxic to fibroblasts than
they are to bacterial cells, thereby virtually ruling out its applicability as a therapeutic for dermal
applications.

4.3.9

Determining the optimum nanoparticle: antibody ratio for bacterial targeting

4.4

Summary and Conclusion
Bare copper nanoparticles were synthesized using PAA as a capping agent and their size

was in the range of 2nm and 8.2 nm, determined respectively by DLS and TEM. The attachment
of the antibodies to the nanoparticles was done by physical adsorption and the binding yield of the
three different antibodies, two of which were specific for S.aureus and the other for P.aeruginosa,
was determined by fluorescent labeling of the antibodies. The optimized nanoparticle: polyclonal
antibody ratio of 1:1 produced the best binding yield. Chemical crosslinking of the antibodies to
the nanoparticles, via EDC chemistry, resulted in huge aggregation of the nanoparticles and hence
was discarded. Characterization by DLS, showed zeta potential values of greater than -20 mV,
indicating that the PAA-5000 stabilized nanoparticles and antibody-nanoparticle conjugates were
stable in solution; and the UV-Vis absorption spectra depicted a peak at 590 nm, which indicates
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Figure 4.4: Direct cytotoxicity results of MTT assay that shows the percentage of cell viability after
60 h for 3T3 fibroblasts that were incubated with varying concentration of nanoparticles and two
different ratios of nanoparticle-antibody conjugates (n=3).
a slight shifting of the characteristic absorption peak of copper at 570 nm. This finding suggests
that possible oxidation of these copper nanoparticles into CuO nanoparticles may take place when
transferred into DI water (neutral pH) from a basic pH. A 1:1 nanoparticle: polyclonal antibody
ratio was also shown to be optimal in targeting bacterial cells compared to initial ratios of 10:1
and 1:10. These results show that identification of the optimal nanoparticle: antibody ratio that
maximizes both binding yield and targeting is crucial in obtaining the best possible results. This
finding was corroborated by the fact that the 1:1 ratio, for both the specific and non- specific
antibody- nanoparticle conjugates, produced a lower MIC than the 10:1 ratio, when targeted against
P.aeruginosa. However, varying the nanoparticle: antibody ratio had no effect on S.aureus; which
was shown to be less susceptible to copper nanoparticles than P.aeruginosa. However, the lack
of antibody specificity during these experiments, calls into question the exact mechanism involved
in this improved targeting. The MTT cell proliferation assay using 3T3 fibroblasts showed 5%
cell viability, proving that the copper nanoparticles and the antibody nanoparticle conjugates were
extremely cytotoxic in the concentration range that they were antibacterial. This therefore virtually
rules out the application of such nanoparticles as topical agents in wound healing, given that the
ultimate goal remains the choice of a product with a superior profile of infection control over host
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cell cytotoxicity.
However, within the hospital environment, clothing and bedding are possible means through
which the spread of infection can take place. Therefore, in terms of potential use, the incorporation
of nanoparticulate coppers and its oxides, into surfaces and other objects could be envisaged.
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Chapter 5

Conclusions and Future
Recommendations
5.1

Conclusions
Postoperative wound site infections remain a major source of illness with approximately

500,000 infections per year, among an estimated 27 million surgical procedures. Such infections
account for approximately one quarter of the estimated 2 million nosocomial infections in the United
States each year which causes about 90,000 deaths each year. More than 70% of the bacteria that
cause hospital-acquired infections are resistant to at least one of the antibiotics most commonly used
to treat them. Hence, there is a frenetic search for alternatives and in this regard, antimicrobial
peptides and metallic nanoparticle like silver and copper, which possess broad spectrum antimicrobial
activity and evince low rates of resistance, are touted to play major roles in leading the fight against
such nosocomial infections. This work looks to achieve two major objectives-1) to tackle surgical
site infections specifically due to hernia meshes, using a novel antimicrobial peptide as a coating and
2) to explore the possibility of using copper nanoparticles as a viable alternative to nanocrystalline
silver; in topical wound dressings by performing the dual role of preventing infections and promoting
wound healing.
1. Work on the antimicrobial peptide coating for hernia meshes demonstrated that:
(a) Both synthetic and biological meshes coated with the enzyme were active against S.aureus,
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the pathogenic species of interest.
(b) Biological meshes show lower enzyme attachment but higher retention, while synthetics, with HydrocoatT M as an exception, showed greater enzyme binding and increased
leaching.
(c) Enzyme activity assay qualitatively proved that the peptide coated meshes cause rapid
bacterial cell lysis and fraction analysis demonstrated that most of the activity is due to
the leached enzyme in synthetics and to a lesser extent in case of biologics.
(d) A one year equivalent shelf life study was successfully performed for StratticeT M , BardT M
and HydroCoatT M . Only, PolyproT M lost activity within this timeframe.
i. In this regard, it was noted that a shorter freezing time and a lower test temperature, during lyophilization and accelerated aging respectively, helped preserve enzyme
activity on the synthetics, which are susceptible to loss of enzyme activity.
ii. Biological mesh seems to possess a symbiotic relationship with the enzyme, wherein
the mesh protects the enzyme from denaturation during aging while the enzyme actually improves the meshs tensile properties as shown by previous studies by Belyansky
et al.
2. The progress made on the second objective was basically restricted to analyzing the infection
control aspect and host cell cytotoxicity of these copper nanoparticles.
(a) Stable 2 nm colloidal copper nanoparticles were prepared using Polyacrylic acid as a
stabilizer. However, UV-vis analysis of these nanoparticles indicated slight red shifting
of its characteristic absorption peak, suggesting that oxidation possibly takes place.
(b) Antibody attachment to nanoparticle was carried out by physical adsorption and optimal
targeting using an initial antibody: nanoparticle ratio of 1:1 was demonstrated. This
ratio showed a six times and ten times lower MIC than the bare nanoparticles, for two
different strains of P.aeruginosa. However, the antibody effect was not significant for
gram positive S.aureus and varying the antibody: nanoparticle ratio did not affect the
MICs.
(c) Also, targeting was not due to strong antibody-antigen interaction as shown by the MIC
studies using a specific and non-specific antibody and this targeting seemed to lose its
64

relevance with increasing nanoparticle concentration as seen in S.aureus, whos MIC was
> 0.7 mg/ml compared to MICS of P.aeruginosa which were 0.15mg/ml and 0.06 mg/ml
for the two strains.
(d) MTT cell viability assay showed that the copper nanoparticles and their antibody conjugates were more toxic towards fibroblasts than bacteria, even at sub MIC concentrations,
thereby practically ruling out its applicability as a topical wound healing agent.

5.2

Future Recommendations

1. Further in vitro analysis needs to be carried out on our peptide coating to better understand
the following aspects:
(a) Experiments which delineate the various parameters affecting lysostaphin stability during
accelerated aging need to be carried out.
(b) Also changes to mesh properties upon freeze drying and a case by case analysis of the
practical applicability of lyophilization, as a means of stabilizing the enzyme coating,
needs to be carried out; as some biological matrices are stabilized in buffer solutions, and
may be destabilized in vivo by this process.
(c) Biocompatibility and bioburden analysis needs to be carried out for such enzyme coated
meshes to prove its practical applicability in vivo and to obtain regulatory approval.
(d) Finally, optimum e beam sterilization dosages, that dont affect enzyme activity, need to
be determined for synthetics.
2. In the case of the synthesized copper nanoparticles, further studies need to be conducted on:
(a) Possibly preventing the oxidation of the metallic copper nanoparticles into CuO and Cu2O
nanoparticles which exhibit greater MICs against the clinically relevant pathogens.
(b) Understanding the exact mechanism of antibody directed targeting and the reason for
lack of antibody specificity against the respective antigen.
(c) Characterizing and studying changes to the properties of these nanoparticles when conjugated to the antibody.
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(d) To determine the optimum pH or working conditions that maximizes the potency of these
nanoparticles and their conjugates.
(e) To possibly encapsulate these particles into a biocompatible matrix thereby preventing
host cytotoxicity while selectively attracting bacteria into it by providing directional cues.
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